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Zusammenfassung
Physikalisches und klinisches Potential von zeitversetzten PET/CT-Messungen
nach Strahlentherapiebehandlungen mit Protonen
Bei der Behandlung von Krebserkrankungen mit Protonenstrahlen ko¨nnen empfindliche
Gewebestrukturen direkt hinter dem Zielvolumen durch den schnellen Dosisabfall am Ende
der Reichweite von Protonen vor Strahlung geschu¨tzt werden. Dieser ernorme Vorteil von
Protonen wird jedoch nicht immer voll genutzt, da die Behandlungsplanung und -durchfu¨hr-
ung oft schwer einscha¨tzbare Unsicherheiten beinhaltet. Die erfolgversprechendste In-Vivo-
Methode zur nicht invasiven Kontrolle von Protonenstrahlbehandlungen ist die Positron
Emissions Tomographie (PET). Positronenemitter, wie zum Beispiel 11C und 15O, werden
bei nuklearen Reaktionen entlang des Strahlengangs produziert und ko¨nnen als ra¨umliche
Indikatoren fu¨r die deponierte Dosis genutzt werden. So lassen sich PET/CT-Messungen als
Qualita¨t sichernde Maßnahme zur U¨berpru¨fung der tatsa¨chlich verabreichte Dosis und zur
Quantifizierung von Unsicherheiten nutzen.
In dieser Arbeit werden die physikalischen und klinischen Mo¨glichkeiten von zeitverset-
zten PET/CT-Messungen zur Behandlungskontrolle untersucht. In einer Phantom-Studie
wird die physikalische Reproduzierbarkeit, die Konsistenz und die Sensivita¨t der Meth-
ode erkundet. In einer Patienten-Studie wird ihre klinische Leistungsfa¨higkeit qualitativ
und quantitativ betrachtet. Dafu¨r werden Daten von 23 Patienten (9 Patientendatensa¨tze
wurden vor, 14 im Rhamen dieser Arbeit gesammelt) mit vielfa¨ltigen Tumorerkrankungen
unterschiedlicher Art und Lokalita¨tern analysiert. Es werden Patientenuntergruppen bes-
timmt, die aus der Anwendung der Methode am meisten profitieren. Daru¨ber hinaus werden
technische und methodische Verbesserungen untersucht, die eine breitere Anwendbarkeit
von PET/CT-Messungen zur Behandlungskontrolle bei der Strahlentherapie mit Protonen
ermo¨glichen.

Abstract
Physical and Clinical Potential of oﬄine PET/CT Imaging after Proton
Radiotherapy
The rapid fall-off of dose at the end of range of proton beams has the potential of sparing
critical structures just distal to the target volume. This tremendous advantage of protons
is, however, not always used to its full extent, because treatment planning and delivery in
proton radiotherapy often implies unpredictable uncertainties. The most promising method
for an in vivo and noninvasive monitoring of proton radiotherapy is positron emission tomog-
raphy (PET). Positron emitters such as 11C and 15O are produced via nuclear interactions
along the proton beam path, and can be imaged as a spatial marker of dose deposition. This
way PET/CT imaging can be employed as a quality assurance tool, to verify the actually
delivered dose, and to quantify uncertainties.
In this thesis we investigate the physical and clinical potential of oﬄine PET/CT imaging
for proton treatment verification. In a phantom study we determine the physical repro-
ducibility, consistency, and sensitivity of the approach. The presented patient study quali-
tatively and quantitatively evaluates its clinical performance. Data of 23 patients (9 patient
data sets were acquired before, 14 within the framework of this work) with various tumor
sites are analyzed. The influence of different challenging factors is studied with respect to
different tumor locations. This way patient subgroups that benefit most from the approach
are determined. Furthermore, possible technological and methodological improvements to
allow for a wider applicability of PET/CT treatment verification are identified.

Preface
This PhD thesis was carried out at the Massachusetts General Hospital (MGH) between
January 2006 and January 2009. The thesis describes the approach to verify dose distribu-
tions, delivered during the course of fractionated radiotherapy with protons, by PET/CT
imaging.
Parts of this work have already been published in a paper called ”Quantitative assess-
ment of the physical potential of proton beam verification with PET/CT” [Kno08c] and a
second paper called ”Proton beam range verification with oﬄine PET/CT scans - Clinical
performance challenges and limitations” [Kno09], which will be submitted soon. Chapter
4 is mainly covered by the first papers [Kno08c], while chapter 5 widely presents the con-
tents of the second paper [Kno09]. Parts of the work were presented at five international
conferences [Kno07, Kno08a, Kno08b, Kno08d, Shi08]. For the contribution at the AAPM
Conference 2007 in Minneapolis [Kno07], a second place as young investigator was awarded.
The contribution at the ESTRO Conference 2008 in Gothenburg [Kno08d] was honored with
the ESTRO Varian Research Award.
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1. INTRODUCTION
1.1 Cancer: disease and treatment
Cancer is a synonym for a suite of diseases with very different symptoms and courses. Ac-
cording to the American Cancer Society, 7.6 million people died from cancer in the world
during 2007 [Acs07], corresponding to about 13% of all deaths per year [Who06]. For more
than hundred years, researchers have explored the causes of cancer, have searched for diag-
nostic tools, and researched options for cure. The reasons for cells loosing operator control
and turning cancerous are complex. Nearly all cancers are caused by abnormalities in the
genetic material of the transformed cells. These abnormalities may be due to the effects
of carcinogens such as tobacco smoke, radiation, chemicals, or infectious agents. Educa-
tion campaigns and laws that restrict smoking in public attempt to decrease the cancer
risk due to tabacco consumption. Radiation protection regulations and environmental leg-
islation try to ameliorate the risk for cancer due to radiation and chemicals. The Nobel
prize awarded development of a vaccine against cervical cancer raises the hope to control
infectious agents as causes of cancer. However, besides these somehow controllable effects
other cancer-promoting genetic abnormalities are acquired randomly through errors in DNA
replication or are inherited and thus present in all cells from birth.
The possibilities and strategies of cancer therapy are as manifold as the manifestations of
cancer. Cancer can be treated by surgery, chemotherapy, radiation therapy, immunotherapy,
monoclonal antibody therapy or other methods. The choice of therapy depends upon the
location and grade of the tumor, the stage of the disease, and the general state of the patient.
The ultimate goal of cancer treatment is the complete removal of the tumor without damage
to the rest of the body. The earlier the cancer can be diagnosed the more probable it is that
this can be accomplished by surgery. However, the propensity of cancers to invade adjacent
tissue or to spread to distant sites by microscopic metastasis often limits the effectiveness
of surgery. Chemotherapy is the treatment of cancer with drugs that can destroy cancer
cells. Chemotherapy drugs interfere with cell division in various possible ways, e.g. with
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the duplication of DNA or the separation of newly formed chromosomes. Most forms of
chemotherapy target all rapidly dividing cells and are not specific for cancer cells. Hence,
the effectiveness of chemotherapy is often limited by toxicity to healthy tissues in the body.
Aside from surgery and chemotherapy, radiation therapy is one of the three main options
for treating tumors in patients. Radiation therapy (or radiotherapy) is the medical use of
ionizing radiation to control malignant cells. Radiotherapy can be used as palliative treat-
ment, where a cure is not possible and the aim is local disease control or symptomatic relief.
Furthermore radiotherapy offers the possibility of therapeutic treatment, with the chance to
cure the disease. Radiation therapy has been in use as a cancer treatment for more than
100 years, with its earliest roots traced from the discovery of X-rays in 1895. The concept of
therapeutic radiation was invented by the German physicist Wilhelm Conrad Ro¨ntgen. The
field of radiation therapy began to grow in the early 1900s largely due to the groundbreaking
work of Nobel Prize-winning scientist Marie Curie-Sklodowska, who discovered the radioac-
tive elements polonium and radium. This began a new era in medical treatment and research
[UoA]. Radium was used in various forms until the mid-1900s when cobalt and caesium units
came into use. Medical linear accelerators have been developed since the late 1940s. With
Godfrey Hounsfields discovery of computed tomography (CT), three-dimensional planning
became a possibility and created a shift from 2-D to 3-D radiation delivery. Orthovoltage
and cobalt units have largely been replaced by mega voltage linear accelerators, useful for
their penetrating energies and lack of physical radiation source. In the last few decades, the
advent of new imaging technologies, e.g., magnetic resonance imaging (MRI) in the 1970s
and positron emission tomography (PET) in the 1980s, as well as new radiation delivery and
visualization products has moved radiation therapy from 3-D conformal to intensity mod-
ulated radiotherapy (IMRT) and eventually to image guided radiotherapy (IGRT) in the
near future. These advances have resulted in better treatment outcomes and fewer side ef-
fects. Now 70% of cancer patients receive radiation therapy as part of their cancer treatment.
While the majority of irradiation involves high energy photons, there is a rising inter-
est in treatments with proton beams as the number of clinical proton therapy facilities
increases worldwide. The first suggestion that energetic protons could be an effective treat-
ment method was made by Robert R. Wilson in a paper published in 1946 [Wil46] while he
was involved in the design of the Harvard Cyclotron Laboratory (HCL). The first treatments
were performed at Particle accelerators built for physics research, notably Berkeley Radia-
tion Laboratory in 1954 and at Uppsala in Sweden in 1957. In 1961, a collaboration began
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between HCL and the Massachusetts General Hospital (MGH) to pursue proton therapy.
Over the next 41 years, this program refined and expanded these techniques while treating
9116 patients before the Cyclotron was shut down in 2002. Following this pioneering work,
the first hospital based proton treatment center in the United States was built in 1990 at
the Loma Linda University Medical Center in Loma Linda, California (LLUMC) (recently
renamed the James M. Slater Proton Therapy Center). This was followed by The Northeast
Proton Therapy Center at Massachusetts General Hospital (recently renamed the Francis H.
Burr Proton Therapy Center), to which the HCL treatment program was transferred during
2001 and 2002.
1.2 The need of treatment verification tools
One of the major advantages of proton therapy and heavy charged particle radiation therapy
in general, is the possibility to deliver a high tumor dose while minimizing dose to healthy
tissue. While penetrating material, electromagnetic as well as hadronic forces act on the
ions. The most important interaction is the electromagnetic Coulomb interaction between
the projectile and electrons, through which the ions continuously lose energy. The loss of
energy increases with increasing depth of penetration. The description of this phenomena
due to the Bethe-Bloch [Bet30, Blo33] equation leads to the characteristic depth dose curve
for ions, known as the Bragg curve. The Bragg curve is characterized by a relatively low
dose in the entrance region and a high-dose peak in the target. The finite beam range is the
main advantage of the use of protons in radiation therapy. However, due to the steep dose
gradient at the distal edge of each individual beam, uncertainties in the dose calculation and
in the treatment delivery can have a profound impact on the applied dose. Slight errors may
result in severe under dosage of the tumor volume and over dosage of the surrounding critical
structures. Discrepancies between planned and actual delivered dose can be due to patient
specific uncertainties like setup errors, motion and anatomical changes [Eng05]. Further-
more dosimetric uncertainties, like errors in the treatment planning algorithm, artifacts in
the planning CT and ambiguity in the Hounsfield Unit (HU) conversion [Jia07] contribute to
differences between planned and delivered dose. Solely the conversion from HU to stopping
power can lead to a range uncertainty of about 1 - 3 mm in a typical treatment situation
[Sch98].
Because of the steep dose fall-off, a very precise treatment delivery is important and
3
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strategies to verify the actual delivered dose and in particular the beam range in the patient
are required. The complete stopping of the protons in the patient prevents the application
of electronic portal imaging methods used in conventional radiotherapy. At present, the
most promising method for in vivo and noninvasive monitoring of radiation treatments with
proton beams is PET imaging.
A short historical overview of the use of PET imaging for proton treatment verification
was given in [Par04]. Pioneering and very preliminary investigations on the potential of 2D
on line imaging of β+-emitting target fragments (mainly 11C, 15O and 10C) induced by proton
irradiation of phantoms and animals were carried out in Brookhaven at the end of the 1970s
[Ben75, Ben78]. Starting from the beginning of the 1990s the topic was again addressed
in preliminary phantom experiments using an on-line 2D array of scintillating detectors of
low spatial resolution operated in coincidence as well as a commercial off-line PET system
[Lit93, Lit99]. In the same year simulation studies [Del94] as well as off-line PET measure-
ments after proton irradiation of phantoms [Paa93, Oel96] and of one patient [Vyn93] were
done by various groups. Despite the common agreement on the potential usefulness of PET
imaging for proton therapy monitoring, no definitive conclusion on the clinical feasibility and
effectiveness was drawn. The lack of activation in the few last millimeter of penetration due
to the energy threshold of about 15 - 20 MeV for the proton induced nuclear reactions, as well
as the poor spatial correlation between β+-activity and dose depth profiles were recognized
as a nontrivial complication for the extraction of range information and dose localization
[Oel96].
Instead of comparing the measured activity distribution and the dose distribution for
treatment verification the challenge of their complex relation can be overcome by the use of
predicted β+-activity distributions. Following the approach of treatment monitoring for car-
bon ion therapy [En99, Poe04], detailed Monte Carlo (MC) simulated activity distributions
can be used for validation [Par00, Par07c]. Alternatively, an analytical approach based on
Gaussian power-law convolutions was proposed to calculate the expected activity distribu-
tions [Par06]. Extensive in beam phantom experiments carried out with proton beams at
the Association for Heavy Ion Research (GSI) Darmstadt, Germany strongly encouraged the
applicability and the accuracy of the method when comparing measured and expected activ-
ity distributions [Par02, Par05]. A recent phantom study [Par07a] and a clinical pilot study
[Par07b] on a small population of 9 patients investigated the feasibility of oﬄine PET/CT
treatment verification for proton radiotherapy on site at MGH. It was shown that the beam
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range could be verified within an accuracy of 1 - 2 mm in low perfused bony structures of
head and neck patients, for which an accurate co-registration of predominate bony anatomy
was possible. At other positions and for other tumor sites, however, millimeter-accurate
range verification failed. The most likely reason was attributed to limitations of washout
and rigid co-registration, as well as motion uncertainties in the prolonged scan time of 30 min.
1.3 Aim and outline of the thesis
To employ PET/CT range verification clinically, it is crucial to know whether disagreements
between measured and calculated activity maps reflect errors in the treatment planning,
calculation or delivery, or whether they are caused by inherent limitations of the method.
The aim of this thesis is the qualitative and quantitative specification of the physical and
the clinical potential of oﬄine PET/CT treatment verification.
The physical potential of the oﬄine PET/CT approach, independent of and unaffected
by other factors, is investigated in a comprehensive phantom study. The data analysis aims
to:
• Test the reproducibility of the measured PET signal. The irradiation and PET scan
of a phantom are repeated twice and activation depth profiles at identical geometrical
positions within the phantom are compared.
• Test the consistency of the measured PET signal. Activation depth profiles within
identical material arrangements, but at different positions within the irradiation field,
are compared.
• Investigate the sensitivity of the PET/CT range verification method. Activation depth
profiles through air/lung, air/bone and lung/bone interfaces parallel to the beam di-
rection, as well as 6◦ angled, are studied to determine whether small range changes
due to small tissue inhomogeneities are reflected in the measured PET signal.
The clinical potential is investigated for a larger population of 23 patients (9 patient data
sets were acquired before [Par07b], 14 within the framework of this work) and a variety
of tumor locations including the head, eye, spine, prostate and the sacrum. The following
aspects are addressed:
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• Restrictions on the accuracy of the oﬄine PET/CT range verification method due to
biological washout processes: Range verification ability is compared at positions where
the proton beam ranged out in bone and at positions where the beam ranged out in
well-perfused tissue.
• Effects on the accuracy of the oﬄine PET/CT verification method due to patient
motion: Lateral agreement between measured and simulated activity distributions for
tumors in the thorax and abdomen are compared to the lateral conformity in head and
neck tumor cases.
• Uncertainties in the MC-simulated activity distributions due to the restricted correla-
tion in the mapping of HU to elemental compositions and washout characteristics: HU
domains for different organs in the abdomen and pelvis are determined to investigate
whether the HU mapping is sufficiently correlative to assign organ specific elemental
compositions and washout characteristics in the MC simulations. To test the influ-
ence of uncertainties, MC simulations for different HU mappings are performed and
compared.
• PET/CT range verification ability with respect to the tumor location: Patients were
grouped and average absolute range deviations for different tumor locations were calcu-
lated. Site-specific challenges in addition to the three factors listed above are evaluated
and an importance factor, indicating the degree of limitation on the PET/CT range
verification method at this tumor location, is introduced for each aspect.
The general aim of this thesis is to identify the clinical extent of practicability of the
investigated implementation of PET/CT treatment verification for proton radiotherapy, and
to determine possible technological and methodological improvements to allow for wider ap-
plicability.
This thesis is organized as follows: The second chapter reviews the physical rationale
of proton therapy, briefly describes factors that contribute to uncertainties in proton dose
distributions, and gives an overview of strategies to handle these uncertainties. In chapter
three, the physical background of the oﬄine PET/CT verification approach is described and
strategies how to predict activity distributions are introduced. Furthermore, the clinical im-
plementation of PET/CT range verification from data acquisition to data analysis at MGH
is described. The fourth chapter concentrates on the evaluation of the physical potential of
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oﬄine PET/CT treatment verification, while the fifth chapter explores its clinical perfor-
mance. The conclusions are summarized and discussed in the sixth chapter. An overview on
the work in progress is given in the outlook. The appendix contains a flowchart of all steps
involved in the PET/CT range verification approach, and gives practical advice on input
parameters and adjustments of the different routines that needs to be run for a complete
analysis.
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2. TUMOR THERAPY WITH PROTON BEAMS
2.1 The physical basis of proton radiotherapy
The goal of radiotherapy with external beams is to deliver a dose distribution precisely lo-
calized in the tumor volume, while least affecting the surrounding healthy tissue and critical
structures. As pointed out by R.R. Wilson [Wil46], the main argument for the use of protons
in radiotherapy is their superior physical selectivity due to the lower energy, i.e. dose, in the
entrance channel (plateau) and a steep increase and fall-off towards the end of penetration.
Thus protons are highly suitable to deliver high tumor dose while sparing the surrounding
tissue.
For protons passing through matter, the most important interaction is the electromag-
netic Coulomb interaction with electrons, by means of which the protons continuously lose
energy. The loss of energy increases with increasing depth of penetration. This is due to
the fact that a proton with smaller velocity v has more time to interact with the electrons
of the atom. The energy loss due to Coulomb interactions in a medium with a density ρ is
described through the stopping power S(E) of charged particles with energy E:
S(E) = −1
ρ
∂E
∂z
. (2.1)
For charged particles with masses bigger than the electron mass me, S(E) is analytically
described by the Bethe-Bloch-equation [Bet30, Blo33]. For protons it reads:
S(E) = 0.307
Z
A
1
β2
(
1
2
ln
2mec
2γ2β2Tmax
I2
− β2
)
(2.2)
The kinematic terms β and γ are defined as v
c
and 1√
1−β2
; Tmax denotes the maximum
transferable energy to an electron and I is the mean ionization potential of the particular
medium with the nuclear number A and the atomic number Z. The decrease of energy loss
for charged particles in material as a function of the increasing velocity v becomes apparent
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through the relation S(E) ∝ 1
v2
. The Bethe-Bloch equation together with the statistical na-
ture of the Coulomb interaction for an ensemble of protons [Oel02] leads to the characteristic
depth dose curve for protons, known as the Bragg curve [Bra04].
Besides the electromagnetic Coulomb interaction with electrons, protons also undergo
inelastic hadronic interactions with nuclei. Inelastic hadronic interactions have mainly two
effects on the depth dose curve. As a first consequence the fluence distribution of the primary
particles is exponentially attenuated in depth x according to the expression:
φ(x) = φ0e
−NσRx (2.3)
where φ0 is the initial fluence, σR is the total crossection and N is the atomic density of the
medium. This means the so far discussed depth dose curve for the Coulomb interaction has
to be scaled down by a depth dependent factor. Furthermore, secondary particles produced
in hadronic reactions contribute extra dose. For protons secondary particles can only be
target fragments. Neglecting the heavy target fragments which stay almost at rest in the
interaction place, the most important effect on the energy deposition is rendered by the
production of secondary protons and neutrons liberated in (p, xp’) and (p, xp’yn) reactions.
From this yield only the secondary protons are found to give a significant dose contribution
(up to 10% of the total dose at 160 MeV [Pag02]) in the proximal part of the Bragg-curve
because of the lower energy spectrum with respect to the attenuated primary beam. Fig-
ure 2.1 shows calculated Bragg curves for proton energies between 59.4 MeV to 255 MeV
in steps of approximately 2.5 MeV taking into account electromagnetic as well as hadronic
interactions. The curves were simulated using Geant4 MC code.
The lateral part of charged particle dose distributions at a point with a given water equiv-
alent path length η and a lateral distances x and y from the central ray can be approximated
by a Gaussian distribution with a depth dependent sigma value [Nil01]:
L(η, x, y) =
1√
2piσ2x′(η)
exp
(
− x
2
2σ2x′(η)
)
× 1√
2piσ2y′(η)
exp
(
− y
2
2σ2y′(η)
)
(2.4)
σx′(η) =
√
σ2x + σ
2
MCS(η) (2.5)
σy′(η) =
√
σ2y + σ
2
MCS(η) (2.6)
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Fig. 2.1: 75 MC simulated Bragg curves for proton energies of 59.4 MeV up to 255 MeV
The sigma of the off-axis part of the pencil beam is split into two components.
σx,y: Due to the finite size of the proton source and the scattering of the primary
protons within the nozzle and the air gap between treatment head and patient,
the proton beam already has a lateral extension before it enters the patient. The
values that are used for both sigmas can be obtained by measuring the primary
fluency with an ionization chamber in air.
σMCS(d): The beam broadening inside the patient is due to the multiple Coulomb
scattering of the charged particles, and can be modeled by using a depth depen-
dent sigma value. σMCS values for protons with energies between 59.4 MeV to
255 MeV in steps of approximately 2.5 MeV taking into account hadronic interac-
tions are shown in Figure 2.2. The curves were simulated using Geant4 MC code.
Most tumor volumes are extended spatially and therefore demand three dimensional, uni-
form dose distributions. The longitudinal widening of the dose distribution is accomplished
by a proper superposition of several Bragg-peaks of different depths to a spread out Bragg-
Peak (SOBP). This can be either obtained through passive energy degraders (modulation
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Fig. 2.2: σMCS distribution for protons with energies between 59.4 MeV and 255 MeV.
wheel) or active variation from the accelerator energy. A lateral spread of the dose distri-
bution is achieved either by broadening the transverse beam profile by means of scattering
systems, or by exploiting lateral magnetic deflection of pencil-like proton beams. To laterally
shape a passively scattered broad treatment field to a desired target profile, custom milled
apertures can be used. The distal part of the dose distribution can be shaped according to
the desired treatment field using patient specific milled compensators. Figure 2.3 shows a
sketch of the beam modeling devises used at MGH.
2.2 Uncertainty factors
Due to the steep dose gradient at the distal edge of proton beams, uncertainties can have a
profound impact on the applied proton range. The numerous sources of uncertainty can be
classified in patient and physics related.
Motion is one of the main patient related uncertainties. During treatment, motion can
either cause density changes of traversed tissue (for example breathing motion during lung
treatment), or displacements of different tissues within the beam path (for example bowel
12
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Fig. 2.3: Sketch of beam line element in the gantry-treatment rooms at MGH: 1. First scatterer,
2. Modulation wheel, 3. Second scatterer, 4. Patient specific aperture and 5. Patient
specific range compensator
motion during prostate treatment) that effect the residual proton range [Eng05, Zha07].
Another patient related uncertainty factor is the daily setup. For prostate patient small
variations in the leg positioning lead to different fractions of bone in the beam path which
modify the proton range [Xu08]. Furthermore, during the course of fractionated proton treat-
ment, the patient contours can change due to weight loss or gain. If this geometry change is
not considered in the planned dose distribution it leads to deviations between planned and
actual delivered proton range [Al08].
An example for a physics related uncertainty is the CT number conversion. For proton
treatment planning CT Hounsfield numbers have to be translated in relative stopping pow-
ers. Empirical conversions are experimentally validated in tissue substitutes or samples, but
cannot be directly verified within the patient [Schn96, Sch98, Schn00, Jia07] and thus con-
tain uncertainties. Furthermore, the segmentation of the tumor and the critical structures
based on medical images is inherently uncertain and error prone. For example CT artifacts
can result in range overestimation at positions where a proton beam travels along a shaded
region or to range underestimation at positions, where artifacts prevent an exact implant
delineation [Ja¨k07]. Another source of physics related uncertainties of the proton range in
radiotherapy is the dose calculation. Conventional treatment planning algorithms, based
on pencil-beam dose calculations, have a limited capability to handle dose degradation due
13
2. TUMOR THERAPY WITH PROTON BEAMS
to Coulomb scattering in complex tissue inhomogeneities. Finally the dose delivery itself
presents a source for uncertainties in the proton range.
2.3 Strategies to handle uncertainties
There are a variety of strategies to monitor and control each source of uncertainty in pro-
ton radiotherapy. Advances in 4D medical imaging, including time-resolved volumetric CT,
magnet resonance imaging (MRI), PET, PET/CT, single photon emission computed tomog-
raphy (SPECT) and ultrasound (US) allow to study, characterize, and minimize patient
motion during the processes of imaging and radiotherapy [Li08]. To quantify the water
equivalent path length variations resulting from respiration, analyzing tools based on 4D CT
data [Mor08] have been proposed. The availability of advanced in-room imaging like cone-
beam CT enables an on-line 3D target setup not limited to external patient information
[Thi06]. Low-cost daily patient imaging detects and helps to account for contour changes in
the patient during the course of fractionated proton treatment.
One promising way to handle the physics related problem of imprecise stopping powers for
different tissue from conventional CT data is proton radiography [Koe68]. Through proton-
computed tomography (pCT) direct information about the stopping powers of the therapy
beam can be gained [Schn95]. Recent publications investigate the density and spatial resolu-
tions of proton radiography [Ryu08] and report on the first proton radiography of an animal
patient [Schn04]. One way to conquer deficiencies in conventional treatment planning is
provided by MC simulations. MC methods have been applied to verify the results of the ap-
proximate dose calculation algorithms implemented in commercial treatment planning tools
[Car97, Ma00]. They are considered to be the most accurate method to compute doses in
radiation therapy, because simulations take into account the physics of particle interactions
on a particle-by-particle basis using theoretical models or experimental cross-section data for
electromagnetic and nuclear interactions [Pag08]. Currently, however, MC based treatment
planning is not commercially available, mainly because of time inefficiency.
The tools mentioned thus far are only capable of controlling or monitoring specific sources
of uncertainties. For treatment and quality assurance, in vivo verification tools that monitor
all involved sources for range uncertainties are desired.
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The unique time dependence of the dose rate function produced by range-modulated,
passive-scattered protons was investigated recently for the use of in vivo range verification
[Lu08]. By measuring such time dependence at the points of interest, the residual range
of the proton beam at these points can be readily determined with millimeter accuracy, as
long as these points fall in the plateau of the SOBP depthdose distribution. This approach
would be capable of handling interactive adjustment of the proton range. However it only
permits point wise verification of the delivered range and is limited to tumor sites that allow
intra-cavity dosimeters in the beam path or implantable dosimeters with time-resolved ex-
ternal read-out. Another attempt for in vivo range verification is the use of prompt gammas.
MC studies [Seo06] and preliminary experimental studies [Kie89, Min06, Bel07] indicate a
correlation between the gamma distributions and the distal falloff region of proton beams.
While this technique is very promising to verify the range at each position in the patient
for scanned proton beams, it does not permit three-dimensional range verification in broad
scattered proton beams.
PET/CT imaging is currently the only promising tool for in vivo range verification in
passively scattered proton beams. It offers the unique advantage of direct verification of the
applied three-dimensional contour of the distal dose ends.
15
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3.1 The physical basis of PET imaging
In proton radiotherapy positron emitters are produced as a by-product in the penetrated
tissue, as illustrated in Figure 3.1. Besides electronic interactions, protons undergo nuclear
interactions where they can separate neutrons from nuclei in the tissue. The residual nuclei
then undergo β+-decays where a proton turns into a neutron under emission of a positron
and a neutrino. Then, the positron annihilates with an electron from the surrounding tissue
under emission of two photons in opposite directions which can be detected by PET scanners.
Fig. 3.1: β+ decay: 1. Neutron separation, 2. Positron emission and 3. Positron annihilation.
β+-emitting target fragments are produced along the penetration path until the energy
of the primary protons drops below the threshold of nuclear reactions, which typically cor-
responds to few millimeters residual range in tissue. Energy thresholds for the main (p,pn)
reaction channels leading to the production of 11C and 15O are 16.6 MeV and 20.3 MeV,
respectively [Vyn93]. Experimental cross sections for (p,pn) channels yielding in positron
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emitters 11C [Vas60, Gau62] and 15O [Alb62, Saj85] are shown in Figure 3.2 [Nuc00]. Besides
11C and 15O also small fractions of 10C, 13N, 30P and 38K are produced.
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Fig. 3.2: Experimental cross section for the (p,pn) reaction on 12C and 16O nuclei [Nuc00].
The predicted total amount of β+ emitters and the devision into the different nuclei pro-
duced within the treatment volume by a therapeutic proton irradiation of 1 Gy(RBE) target
dose is shown in Figure 3.3. Gy(RBE) dose was computed using an REB of 1.1 for proton
beams. The quantitative analysis in [Par04] supported the feasibility of PET signal detec-
tion during or shortly after a therapeutic proton irradiation. For on line data acquisition the
signal from 12C and 16O nuclei is comparable as shown in the left graph of Figure 3.3. The
12C fraction increases relative to the 16O fraction with increasing delay between irradiation
and PET scan as shown in the right graph of Figure 3.3. This is due to the different half-life
T1/2=20.39 min and T1/2=2.03 min for
12C and 16O, respectively.
The produced neutron deficient nuclei can undergo a β+ decay, where a positron e+ and
an electron neutrino νe is emitted:
A(Z,N)→ A(Z − 1, N + 1) + e+ + νe (3.1)
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Fig. 3.3: Total and pro rata depth activity distribution from 11C, 15O, 13N, 30P and 38K produced in
a patient by proton irradiation resulting in 1 Gy(RBE) target dose according to FLUKA
[Par07c] predictions at time 0 min (left) and 5 min (right) after the treatment. The
calculated depth dose profile is additionally shown.
In this three-body decay the positron can share the available energy with the neutrino in an
arbitrary proportion. Thus the energy spectrum of the positron is continuous up to max-
imum possible energy values. For the most abundant induced isotopes 11C and 15O these
values lie between 1 and 2 MeV. The distance a positron travels through matter before it
annihilates with an electron is a function of its initial energy and the electron density of
the medium, and is typically ' 4.5 ...10 mm in tissue. While the positron travels through
tissue it loses energy in inelastic Coulomb collisions with atomic electrons and suffers several
angular deflections. Once almost at rest, the positron either annihilates with an electron of
the medium into two photons or captures an electron to form an unstable bound state. Pos-
sible bound states either annihilate into two or three photons. The 3γ-emission is however
negligible and all the detectable radiation can be attributed to the 2γ annihilation.
The photons are emitted at almost 180◦ in opposite direction and carry each an energy
of 511 keV equal to the positron and electron rest mass. The γ-ray pairs are isotropically
emitted in the full solid angle of 4pi and can be detected by couples of opposite detectors op-
erated in coincidence. With tomographic acquisition techniques and suitable reconstruction
algorithms it is possible to retrieve the spatial distribution of the β+ activity source. The
two basic assumptions of the reconstruction are that (i) the nucleus from which the positron
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originated is exactly located along the line at which the two photons are emitted and (ii)
the two annihilation photons are emitted at 180◦[Ben98].
The limited validity of the assumptions for the reconstruction algorithm, for example
due to the distance the positron travels before annihilation, restricts the intrinsic achievable
resolution of PET to 2-3 mm [Wie89]. This value is however below the ' 5 mm practical
spatial resolution of current commercial PET scanners. Their resolution is mainly deter-
mined by the dimension of the single detector units. Furthermore the attenuation of the
photons within the scanned object, as well as the detection of random and scattered coin-
cidence affect the measured data. These effects can however be well quantified and corrected.
A mono energetic proton beam and an SOBP proton field with the same maximal energy
result in almost the same induced activity distribution, as shown in [Oel96] . This indicates
that a depth dose profile cannot be uniquely determined from the proton induced activity
pattern. Therefore this study mainly concentrates on the range verification rather than on
the complete spatial verification of the dose distribution. The position of the distal activity
fall-off is mainly influenced by the energy thresholds for the (p,pn) reaction channels leading
to the production of 11C and 15O. The distance between the 50% level of the distal edge of the
total positron emitter distribution and the dose maximum varys slightly, depending on the
residual proton range at energies below the reaction thresholds and on the carbon to oxygen
ratio of the medium composition. Depending on the time course of irradiation and the delay
to the beginning of imaging, different isotopes contributed to the measured PET signal in
a different extent as seen in Figure 3.3. Furthermore, biological washout effects redistribute
the induced β+ emitters. Ways to model these effect were introduced in [Par07a] and are
described in subsection 3.2.1.
Because of the complex relation between dose and activity distribution, range verification
has to be performed by comparing measured PET images with realistic predictions based
on the individual treatment plan of the patient and the time course of the specific irradia-
tion. Ways to perform reliable predictions of the induced activity pattern were described in
[Par06, Par07c] and are discussed in section 3.2. Either CT-based MC simulated distribu-
tions as described in subsection 3.2.1 or analytical calculated distributions as described in
subsection 3.2.2 can be used, both complemented by functional information.
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3.2 Realistic prediction of induced positron emitters
3.2.1 MC simulations
As described in section 3.1 an essential step in the PET/CT treatment verification approach
is the comparison of the measured activity distribution with calculated activity distribu-
tions. MC simulations based on the treatment plan, the planning CT data and the time
course of irradiation and imaging provide a very realistic prediction for the induced activity
pattern [En99, Poe04, Par07a, Par07c] due to the statistical nature of the involved processes.
The MC framework for the PET/CT range verification approach was mainly developed
prior to the work of this thesis. MC simulations used in this work are based on two codes.
The proton beam phase-spaces were obtained from GEANT4 based simulations [Ago03],
which modeled the entire nozzle of our proton therapy facility [Pag04]. Although GEANT4
has been successfully employed for clinical dose calculations at the Francis H. Burr Proton
Center [Jia04], the FLUKA MC code [Fas03, Fer05] was preferred to simulate the spatial
activity distribution due to the traditional reliability of the FLUKA nuclear models [Pag03]
and the good agreement with experimental PET data [Par02, Par05]. Besides activity pat-
terns, dose, i.e., energy deposition per volume divided by the real density, was calculated
for comparison with the treatment plan. All simulations were performed using phase spaces
of about one million protons, corresponding to 3% (PET) and 5% (dose) statistical uncer-
tainty, as a compromise between the conflicting requirements of sufficient statistics and low
computational time. For normalization, an additional FLUKA simulation with the same
input phase-space was performed in the water tank used for quality assurance dosimetry.
An idivitual normalization factor for each treatment field (n ≈ (1− 7)× 103) is given by the
ratio of the prescribed to the simulated dose to water at isocenter.
Expected activity patterns were obtained from the simulation of the spatial distribution of
positron emitters produced in tissue as described in [Par07b]. Positron emitter distributions
were calculated by combining proton fluency with experimental cross sections. Besides the
main (p,pn) channels on 12C and 16O, yielding 11C and 15O [Par02], respectively, further pro-
ton interactions with N, O, Ca, and P, resulting in 11C, 13N, 38K, and 30P production, respec-
tively, were included. Shorter-lived emitters were neglected because of the low-production
cross-sections and the oﬄine PET imaging approach.
To get a realistic prediction for the measured activity distribution all involved effects,
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i.e. biological washout, scanner responds and image reconstruction have to be taken into
account in the simulation. The spreading of the induced positron emitters due to biological
washout processes is taken into account by means of space (i.e., tissue) and time-dependent
weighting factors as described in [Par07b]. Previous animal studies on the washout of 10C
and 11C implanted ions, or 11C resulting from auto activation of 12C beams, indicated the
existence of a fast (biologic half-life T1/2,biof ≈ 2 − 10s), medium (T1/2,biom ≈ 100 − 200s),
and slow (T1/2,bios ≈ 3, 000 − 10, 000s) component of biologic decay in rabbit thigh muscle
and brain [Tom03, Miz03]. The fast and medium processes have already decayed in our
oﬄine approach at the time of imaging. Following the mathematical formulation of [Miz03],
the slow biological effect is introduced as a space-dependent (i.e., tissue) and time-dependent
weighting factor of the physical activity:
Cbios(r, t) =MS(r) exp(−λbios(r)t). (3.2)
Values of the relative fraction MS, and biologic decay constant λbios = loge2/T1/2,bios are,
however, unknown for the various isotopes in human tissues. For the sake of simplicity,
tissue is classified into low, intermediate, and normal perfused, and differences between the
metabolisms of different isotopes are neglected. Thresholds are set on the planning CT to
identify fat (-150 ≤ HU ≤ -30), soft bone (200 ≤ HU < 1000) and compact bone (HU
≥ 1,000). For the low-perfusion fat and compact bone, MS and T1/2,bios are set to 0.9 and
15,000 s, respectively. In soft bone, intermediate values of MS and T1/2,bios are approximated
to 0.6 and 8,000 s. For all remaining tissue, an average value of MS = 0.55 and T1/2,bios =
3,500 s is used in spine sites, while a value of MS = 0.35 and T1/2,bios = 10,000 s is used for
head sites, based on the results of animal studies in muscle and brain, respectively [Miz03].
While the biological washout processes are not only different for different tissues, they also
possibly vary from day to day, or in respect to the time point of PET imaging during the
treatment course. Radiation can have a significant influence on the metabolism of tissues
as shown in [Kes08], which can for example result in different oxygen levels in tissues at
different phases of treatment.
For full-ring tomography, blurring from image formation and reconstruction can be rea-
sonably modeled by a three-dimensional (3D) Gaussian convolution kernel G(r) according
to [Par07a, Par07b]. A PET image, averaged on a time frame of duration tframe starting
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with a time delay ∆tt after the end of irradiation can be obtained as follows:
G(r) ∗
(∑
i
ni ·
∑
j
[MS(r)Nij(r) · [1− exp(−λjtirr,i)]
tirr,i
· exp(−λtot,j(r)∆t) ·
[1− exp(−λtot,j(r)tframe)]
λtot,j(r)tframe
]
)
(3.3)
This equation adds up the activity contributions from the calculated amount Nij of isotopes
of species j, formed by each delivered field i. ni is the normalization factor for the considered
field, MS is the slow biologic decay fraction, and λj and λtot,j are the isotope-specific physi-
cal and total (i.e., physical plus biologic) decay constants, respectively. The slow biological
decay during the short irradiation time (tirr,i ≈ 10 to 100 s) is neglected. Figure 3.4 shows
a comparison between a measured and the corresponding MC simulated activity distribution.
Currently, MC simulations of dose and activity distributions are only possible for treat-
ments in the gantry rooms at MGH, since the geometry of the fixed lines is not jet imple-
mented. Problems and uncertainties of the MC approach will be discussed in section 5.4.4.
3.2.2 The filtering approach
A simpler and more direct way to reconstruct the expected PET signal is described in [Par06].
Under reasonable assumptions, the PET image can be described as a convolution of the dose
distribution with a filter function. The reaction depending filter functions can be determined
analytically using convolutions of Gaussian and power-law functions. The advantage of this
filter approach is that the expected activity distribution can be determined locally, in con-
trast to the MC simulation that requires the consideration of all involved processes along
the entire beam path. The filtering approach is thus less sensitive to uncertainty factors like
tissue inhomogeneities or artifacts along the beam penetration.
Activation profiles achieved from the filtering approach have been validated against MC
calculations and measurements in homogeneous and inhomogeneous phantoms [Par06, Att08].
Good agreement in position in depth as well as in terms of absolute intensity could be
achieved. Figure 3.5 shows a preliminary comparison between a measured and the corre-
sponding filtered activity distribution in a patient. In the filtered activity distribution only
the contribution of 11C. For in vivo activity predictions the filtering approach faces several
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Fig. 3.4: Comparison of a measured (upper left) and the corresponding MC simulated (upper right)
activity distribution. The lower figure shows the depth dose distribution at position zero
together with the corresponding activity profiles.
challenges, since it for example does not take into account biological effects due to perfu-
sion and washout processes as well as statistical effects. Similar to the MC approach these
could be added as additional convolution with a Gaussian kernel and probability weighting
factors of the produced activity on the basis of available functional information. However,
the filtering model is also limited to one spatial dimension along the direction of beam pen-
etration. In cases of high curvature of the distal surface of the dose distribution, or for
very small stereotactic fields, an extension of the model to two or three dimensions will be
necessary. Throughout this thesis MC simulated activity distributions are used for valida-
tion mainly because this approach is more common and has been studied by several groups
[Del97, Psh06, Par07c].
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Fig. 3.5: Comparison of a measured (upper left) and the corresponding filtered (upper right) ac-
tivity distribution. For the filtered activity distribution biological washout processes are
not taken into account. The lower figure shows the depth dose distribution at position
zero together with the corresponding activity profiles.
An inversion of the filter functions allows direct dose quantification from the measured
PET distributions. This approach requires PET data of excellent signal-to-noise ratio and
negligible influence of biological processes. Both requirements are somewhat difficult to ful-
fill with off-line imaging strategies. In section 7.3 an overview about the work in progress
concerning the filtering approach is given.
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3.3 Clinical implementation
3.3.1 Procedure at MGH
In the procedure currently performed at MGH suitable patients receive the opportunity to
participate in the Investigational Review Board approved study of PET/CT treatment ver-
ification. The investigational protocol allows for a single or repeated PET/CT scan during
the course of fractionated proton radiotherapy. For repeated PET/CT data acquisition scans
are performed at two different treatment days during one week. Immediately after comple-
tion of one treatment session at the F.H. Burr Proton Therapy Center patients are walked
to the next PET/CT scanner, available within 15 min walking distance. During this study
two PET scanners were used, a Biograph Sensation 16 and a Biograph 64. The PET detec-
tors have a transaxial field of view (FOV) of 605 mm and an axial FOV of 16.2 mm. The
resolution of the PET cameras is about 4.2 mm around the center and 5.5 mm at radiuses
as large as 10 cm. PET/CT data is acquired and reconstructed according to a protocol
specifically designed for this study. The integral distribution of PET activity is obtained
from filtered back projection (FBP) or iterative (ordered subsets expectation maximization,
OSEM) reconstruction of all measured activity data. OSEM reconstructed data is preferred
for data analysis because of reduced fluctuations, especially in the low-activity region at the
edge of the field of interest, allowing for more accurate range verification.
When possible, PET/CT imaging is performed in the same patient position and with the
same immobilization as during the treatment. Differences in patient positioning during irra-
diation and PET/CT imaging are taken into account by rigid co-registration of the planning
CT and the PET-CT performed via commercial FOCAL software (Computerized Medical
Systems, Inc., St. Louis, MO). Images coregistered allows the comparison of the measured
PET distribution with the planned dose and its corresponding PET expectation. The latter
can be obtained from CT-based MC calculation as described in section 3.2 or from an an-
alytical model as described in section 3.2.2, both complemented by functional information.
The whole process from the data acquisition to the data analysis is schematically outlined
in a work flowchart in the appendix.
The clinical pilot study [Par07b] investigated the feasibility of PET/CT treatment verifi-
cation in a small population of 9 patients with tumors in the cranial base, spine, orbit and
eye. Thereafter the patient population was extended to also include abdomino pelvic tumor
sites like prostate and sacrum. Table 3.1 gives detailed information on the tumor site, the
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dose per field, the delay between irradiation and imaging and the number of fields delivered
in each patient at the day of the PET/CT scan. Except for two patients (#22, #23) that
underwent repeated imaging, all patients participated in a single PET/CT imaging after one
treatment session. Irradiation was performed in gantry-equipped treatments rooms except
for two patients (#8, #17) who were treated on a fixed horizontal beam line. PET data were
acquired in list mode at a Biograph Sensation 16 for the first 11 patients and at a Biograph
64 PET/CT scanner for the remaining patients.
For the phantom measurements the same protocol as for the patients was performed. De-
tails are given in section 4.2.
3.3.2 Oﬄine versus on line PET imaging
In this work all results are based on oﬄine PET/CT data acquisition. The long time interval
between irradiation and imaging prevents the acquisition of the contribution from 15O (T1/2
= 121.8 s), which might offer the possibility of addressing tumor hypoxia and treatment
response. A reduction of the time between irradiation and PET/CT imaging possibly also
reduces the influence of biological washout processes. The clinical benefit of on line PET
imaging is however still questionable. Practically, it is hard to find a geometrical scanner
solution within the treatment room that offers comparable 3D data acquisition as in the
oﬄine approach in terms of signal efficiency. Furthermore in room scanners are affected by
scattered treatment radiation and limit the treatment flexibility and the patient through-
put [Cre06]. Due to the limitation to target fragmentation, proton induced PET activity is
especially sensitive to tissue elemental composition. On line data acquisition may be con-
siderably affected by minor target fragmentation reaction channel [Par05]. Since the exact
elemental tissue composition in patients is unknown, these activation channels are difficult
to model. Validation, which depends on predicted activity patterns, becomes more vague the
more activation channels contribute. This source of uncertainty is reduced in the considered
oﬄine scenario, due to the small number of production channels yielding long-lived positron
emitters. Work in progress concerning on line PET measurements at the F. H. Burr Proton
Center is described in chapter 7.1.
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Patient # 1∗ 2∗ 3∗ 4∗ 5∗ 6∗ 7∗ 8∗ 9∗ 10 11 12 13 14
T
u
m
or
lo
ca
ti
on
Head X X X X X X
Eye X
C-spine X X
T-spine X
L-spine X X
Sacrum X
Prostate X
Dose per field [Gy(RBE)] 2 0.9 0.9 2 0.9 0.9 0.9 10 3 1 2 1.8 1 2
Delay between irrad.
and PET/CT imag. [s] 935 984 728 736 993 727 1065
Opposed beam directions X
# of fields
1 X X X X X X
2 X X X X X X X X
Patient # 15 16 17 18 19 20 21 22 22§ 23 23§ total
T
u
m
or
lo
ca
ti
on
Head X X X X X X X 12
Eye 1
C-spine X X 3
T-spine 1
L-spine 2
Sacrum X 2
Prostate X 2
Dose per field [Gy(RBE)] 1 2 0.9 1 1 0.9 1 2.5 2.5 8 8 0.9-10
Delay between irrad.
and PET/CT imag. [s] 686 885 912 852 706 1029 1465 873 830 828 735 ≈ 890
Opposed beam directions X X 3
# of fields
1 X X X X 9
2 X X X X X 13
3 X X 1
Tab. 3.1: Treatment and imaging parameters for the 23 patients that received a PET/CT verifi-
cation scan at MGH. (∗: Patients were reported in [Par07b], §: Repeated PET/CT data
acquisition)
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The use of time of flight (TOF) PET scanners could give a technical advance. Activity
measurements for proton treatment verification are challenged by the low signal compared
to conventional tracer PET images. The poor signal to noise ratio can be substantially
improved by the TOF technique. Scan times can be reduced in TOF scanners to achieve
images similar to those from non TOF scanners, or improved image quality can be achieved
for same scan times [Sur06]. With the time to obtain an image being smaller than the typical
irradiation time, direct TOF-PET could allow accurate, artifact-free images to be shown to
the oncologist in real-time, during the course of irradiation, as long as a corresponding
real-time data acquisition is provided [Cre07].
3.4 Data analysis
3.4.1 Different strategies: 2D
A MATLAB-based (MathWorks, Inc., Natick, MA) code was developed to compare planned
and MC-simulated dose distributions, as well as measured and calculated PET/CT images,
all superimposed or coregistered to the planning CT [Par07a, Par07b]. The Matlab routine
requires a working memory of at least 4 GB and is controlled over the Matlab command
window. The data has to be prepared in advance to fulfill the format obligations. In the
appendix a list of needed input parameters and a detailed description how to prepare the
data for the final analysis is given.
For a first qualitative analysis 2D color-wash distributions of the simulated and measured
activity can be visually compared. Within the framework of this thesis the ability to obtain
2D difference plots that give an idea about the absolute agreement of the two distributions
was implemented. Furthermore, for a quantitative and simultaneous evaluation of absolute
and distance to agreement between measured and simulated activity distribution, the feasi-
bility to perform a gamma index analysis [Low98] was established. Ways to obtain reasonable
absolute values and spatial pass-fail criteria for the gamma index analysis are discussed in
section 5.3.1.
Throughout this thesis absolute values below a threshold of 8% (5%) of the maximum
activity are omitted in the color-wash display (gamma index evaluation) to inhibit the dis-
tracting influence of noise in the measured data.
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3.4.2 Different strategies 1D
Range verification can be performed by comparing depth profiles at 20% and 50% posi-
tion of the last activity maximum in the final distal fall-off region as illustrated in Figure
3.6. Method A will refer to comparing depth profiles at the 20% position and method B
at the 50% position of the last activity maximum. The proper choice of the range verifica-
tion position in the fall-off region in clinical practice is controversial and was discussed in
[Par07a, Par07b, Kno08c]. The 20% fall-off position is more affected by background noise
than the 50% position. Furthermore, the 20% fall-off position in the simulated depth profiles
is sensitive to the chosen FWHM in the Gaussian point-spread function that accounts for
blurring effects and reconstruction. Therefore, the 50% fall-off position is more reliable.
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Fig. 3.6: Illustration of point wise range verification at the 20% and the 50% position of the last
activity maximum in the final distal fall-off region.
Apart from a range comparison at specific positions in the fall-off region, a range analysis
taking the entire fall-off region A(x) into account was established within the framework of
this thesis. The range difference Rdiff between two depth profiles is determined here by
shifting their normalized fall-off regions against each other until the minimum of the sum of
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absolute differences in the activity values Ameas − Aref is found:
Rdiff = argmin
δ
(∑
i∈M
|Ameas(xi)− Aref (xi − δ)|
)
(3.4)
δ typically ranged from -20.0 mm to +20.0 mm in steps of ≈ 0.5 mm. M is a set of indices
with corresponding xi in the interval [xm, xe], were xm is the position of the last maximum in
the activity depth profile and xe is the end of the activity depth profile. The δ for which the
minimum is found corresponds to the range difference between the two depth profiles. The
shift method is currently the most robust analyzing strategy. It is insensitive to gradient
assumptions for the Gaussian point-spread function and the influence of background noise
is negligible. In most cases it gives values between the 20% and 50% fall-off position results.
The accuracy of the method rises with the shallowness of the shifted profile regions. We will
refer to this shift analyzing strategy as method C in this thesis.
Throughout this thesis positions at which range verification failles because of known rea-
sons, such as CT artifacts or the delivery of opposed fields in the same treatment fraction, are
excluded. Large range deviations resulting from an obvious failure of the method of analysis,
for example due to a lack of characteristic similarity in the activity profiles, are also excluded.
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4. PHYSICAL POTENTIAL OF PET TREATMENT VERIFICATION
4.1 Introduction
PET measurements in patients are challenged by several factors. The measured PET sig-
nal is washed out by blood perfusion and can be further blurred by patient motion during
the data acquisition. In addition the comparison of simulated and measured PET images
is affected by the ambiguous translation of CT numbers into material compositions that
introduce uncertainties in the simulated PET image. The rigid image co-registration of the
planning CT and the PET CT, which neglects deformations of the complex patient geometry,
results in further uncertainties. These challenges in the patient measurements are discussed
in detail in the section 5.4.2, 5.4.3, 5.4.4 and 5.4.5. They make it difficult to assess the pure
physical potential of in PET/CT range verification.
The present phantom study investigates the physical potential of PET/CT range verifica-
tion independent of and unaffected by other factors. Emphasis is placed on the qualitative
and quantitative investigation of the measured PET signal. The data analysis aims to:
• Test the reproducibility of the measured PET signal. The irradiation and PET scan of
the phantom were repeated twice and activation depth profiles at identical geometrical
positions within the phantom are compared.
• Test the consistency of the measured PET signal. Activation depth profiles within
identical material arrangements, but at different positions within the irradiation field,
are compared.
• Investigate the sensitivity of the PET/CT range verification method. Activation depth
profiles through air/lung, air/bone and lung/bone interfaces parallel to the beam di-
rection as well as 6◦ angled are studied to determine whether small range changes due
to small tissue inhomogeneities are reflected in the measured PET signal.
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Medium H(%) C(%) N(%) O(%) Mg(%) Cl(%) Si(%) Ca(%) δ(g cm−3)
PMMA 8.05 59.99 31.96 1.18
bone eq. 3.41 31.41 1.84 36.50 0.04 26.81 1.82
lung eq. 8.46 59.38 1.96 18.14 11.19 0.10 0.78 0.30
Tab. 4.1: Elemental composition (fraction by weight) and density of the plastic and tissue equivalent
materials (information provided by the manufacturer Gammex Inc.).
4.2 Methods
4.2.1 Phantom irradiation
The in-house designed phantom consisted of polymethyl methacrylate (PMMA), lung and
bone equivalent tissue slabs (cf. Table 4.1), which were arranged to form air/lung, air/bone
and lung/bone interfaces. These interfaces were positioned once parallel and once in a 6◦
angle to the beam direction. A sketch of the phantom can be seen in Figure 4.1C.
The phantom was irradiated with a 15.7 cm diameter circular spread-out Bragg-peak
(SOBP) proton field of 15 cm and 10 cm water equivalent range and modulation, respec-
tively, to cover the whole geometry. The beam direction was vertical to the material slabs
as shown in Figure 4.1A. It was chosen to deliver a total dose of 8 Gy(RBE) in order to get
a high signal to noise ratio despite the approximately 14 min delay between irradiation and
the PET/CT scan. Besides the main data analysis on the measured activity over the whole
30 min of imaging, also a low-statistics data analysis of only the first 11 min of imaging was
performed. This corresponds to a situation in which only half of the dose would have been
delivered. With this low-statistics analysis way we made sure that the derived results are
also valid for a typical in vivo measurement, where a patient received one or two treatment
fields of ≈ 2 Gy(RBE) at the day of PET/CT imaging.
PET data were acquired in list mode at a Siemens Biograph 64 PET/CT scanner according
the protocol used for patient measurements. The orientation of the phantom was approx-
imately the same at the PET/CT scanner as during the proton irradiation (Figure 4.1B).
Minor differences in the positioning were taken into account by co-registering the planning
CT (voxel resolution: 0.648 mm x 0.648 mm x 2.5 mm) with the PET CT (voxel resolution:
0.4883 mm x 0.4883 mm x 3 mm) which was acquired directly prior to the PET imaging.
For comparison all data sets were superimposed to the planning CT grid after co-registration.
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Fig. 4.1: A) phantom irradiation, B) phantom PET/CT scan and C) phantom layout.
PET image reconstruction was done at 1.3364 mm x 1.3364 mm x 2.025 mm voxel di-
mension which, in consideration of the 4 mm crystal size of the PET detector, was found to
be a good compromise between high spatial resolution and low statistical noise.
4.2.2 Phantom simulation
Validation was achieved by comparing the measured activity distribution with corresponding
MC simulated distributions, that were based on the treatment plan, the planning CT data
and the time course of irradiation and imaging as described in section 3.2.1. All simulations
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were performed using phase spaces of about one million protons (compromise between the
conflicting requirements of sufficient statistics and low computational time). The geometric
information regarding the phantom was extracted from CT. This was preferred compared to
a direct implementation since the phantom geometry contains some irregular shapes. HUs
were segmented into air (HU < -900), lung (-900 ≤ HU < -500), PMMA (-500 ≤ HU <
535) and bone (535 ≤ HU < 2000). The exact elemental compositions and densities of the
materials were assigned to each HU interval. The sharp segmentation of the HU is sensitive
to partial volume effects (PVE). At each interphase, corresponding to at least 3 voxels in
our phantom geometry, a voxel consisting e.g. partly of air and partly of PMMA will be
identified either entirely as air or PMMA. The PVE is not that relevant in typical patient
cases due to the piecewise linearity of the calibration curve and its evaluation at the average
HU value between the two materials. In this phantom study measured activity distributions
were compared to MC simulated activity distributions only relatively. These comparisons
were insensitive to the absolute agreement between measured and simulated activity distri-
butions, and thus to systematic discrepancies of the measurement and the MC simulation.
4.2.3 Testing the reproducibility of the measured PET signal
To test the reproducibility of the measured PET signal, the irradiation and the PET scan of
the phantom were performed twice under nearly identical conditions. Proton range values
measured in the daily quality assurance protocol at our gantry are consistent within 0.3
mm standard deviation over a time of three months. Slight differences in the time course
of irradiation and PET scan between the two measurements are summarized in Table 4.2.
The short interruption in the time course of the first data acquisition was due to a short
interruption in beam delivery. We verified that the impact on the activity depth profiles due
to the small variations in the time course is negligible. For both data acquisitions the same
number of monitor units (MU) was given.
ID tirr(sec) ∆T(sec)
1 138±3 (time course: 0 - 35 (199 MU) + 107 - 210 (589 MU)) 799±3
2 129±3 (time course: 0 - 129 (788 MU)) 756±3
Tab. 4.2: Parameters of the two data acquisitions: ID, irradiation time (time course of irradiation),
delay to the beginning of imaging.
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Even though a single repetition of the irradiation and PET scan of the phantom cannot
statistically ascertain the reproducibility of the method, it gives an indication whether the
method is restricted by the physical reproducibility. The two measured datasets were com-
pared at 12 benchmark positions, which can be seen with respect to the beam position in
Figure 4.2b.
Fig. 4.2: Benchmark positions to test a) the sensitivity b) the reproducibility and c) the consis-
tency of the measured PET signal (red: position in PMMA-air-PMMA, blue: positions
in PMMA-bone-PMMA, green: positions in PMMA-lung-PMMA, profiles of positions
marked with ∗ are shown in Figure 4.4).
4.2.4 Testing of the consistency of the measured PET signal
To test the consistency of the PET signal, we analyzed 16 depth profiles from the first data
acquisition. The benchmark positions with respect to the beam position can be seen in Fig-
ure 4.2c. To test the PET scanner response dependence on the position within the scan field,
we selected pairs of benchmark positions with the same distances to the scanning field origin
for each material arrangement (PMMA-air-PMMA: 1|8, 2|7, 3|6, 4|5, PMMA-bone-PMMA:
2|5, 3|4, PMMA-lung-PMMA: 2|3).
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In addition to the consistency of the PET signal relative to the position within the scan-
ning field (‘global noise’), the consistency with respect to ‘local noise’ was tested. The
comparison of the depth profiles for each material arrangement was done using three differ-
ent average areas perpendicular to the profile direction along the x- and y-axis: a) 1 voxel
in x direction (2.5 mm) / 1 voxel in y direction (0.65 mm), b) 1 voxel in x direction (2.5
mm) / 4 voxels in y direction (2.6 mm) and c) 2 voxels in x direction (5 mm) / 7 voxels in
y direction (4.55 mm). For all benchmark positions the measured ranges were compared to
the simulated ranges to correct for beam divergence effects. The variations in the differences
between measured and simulated ranges reflected the consistency of the PET/CT range ver-
ification method.
4.2.5 Sensitivity of the measured PET signal to anatomical changes
Inhomogeneities and tissue interfaces markedly affect the dose distribution of charged parti-
cles. While the smooth distal dose fall-off translates in a smooth distal activity fall-off in a
homogeneous material, the distal activity fall-off produced by a diluted dose distribution is
not smooth anymore. The relation between the dose distribution and the corresponding ac-
tivity distribution is not straightforward and therefore the ability to accurately monitor the
delivered range behind complex material inhomogeneities cannot simply be devolved from
the situation in a homogeneous phantom. Dose profiles downstream of air/bone, air/lung
and bone/lung interfaces showed that sharp tissue interfaces (0◦) result in a degradation of
the residual range. For more shallow tissue interfaces (6◦) the range degradation smoothed
out [Uri86].
To test the sensitivity to detect those range changes, MC calculated activity depth profiles
and measured activity depth profiles through material interfaces, once parallel (0◦) and once
angled (6◦) to the beam direction were compared. Interfaces between air-lung, air-bone and
lung-bone were considered. The benchmark positions with respect to the beam position for
this study can be seen in Figure 4.2a.
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4.3 Results
4.3.1 Reproducibility of the measured PET signal
Figure 4.3 shows an exemplary comparison of activity depth profiles obtained at two data
acquisitions, and for the benchmark positions shown in Figure 4.2b. The data was corrected
for differences in the absolute activity values due to the different irradiation/acquisition
times (as shown in Table 4.2). The difference in range between the two measurements was
estimated using the three methods A, B and C, as described in section 3.4.2. The results of
the three methods are given in Table 4.3.
Method Position 1 Position 2 Position 3 Position 4
PMMA-air-PMMA
A (meas1-meas2) 0.55 0.11 -0.26 1.46
B (meas1-meas2) 0.16 -0.51 0.28 0.64
C (meas1-.meas2) 0 0 0 -1.30
PMMA-lung-PMMA
A (meas1-meas2) -2.57 -0.77 -1.34 -2.10
B (meas1-meas2) -1.96 -1.17 -0.18 -1.60
C (meas1-.meas2) 1.94 1.30 0.65 1.94
PMMA-bone-PMMA
A (meas1-meas2) -0.45 1.67 1.41 0.48
B (meas1-meas2) -0.91 -0.90 -1.29 -0.29
C (meas1-.meas2) 0.65 -0.65 0 0
Tab. 4.3: Range differences in mm between 2 data acquisitions. Differences were calculated for three
material arrangements (air, lung or bone slab enclosed in PMMA slabs), four benchmark
positions (Position 1-4), and using three methods (A-C).
For all benchmark positions, we see that the differences between the two measurements
at 20% and at 50% of the last activity maximum are similar. Fore some positions the differ-
ences at 20% and 50% have the same sign, which implies that the fall-off regions of the depth
profiles are shifted against each other. for other positions the differences at 20% and 50%
have different signs, which implies that the fall-off regions of the depth profiles have different
gradients. This is confirmed by the shift method, which calculates the best agreement of
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Fig. 4.3: Left: Activation depth profiles for two data acquisitions (solid and dashed line) at 4 po-
sitions through a PMMA-air/lung/bone-PMMA layer. Right: Illustration of the analysis
of the range differences for each layer.
depth profiles with differently signed 20% and 50% range differences for a zero shift.
The average difference between the two measurements at 50% (20%) is 1.1±0.2 mm
(0.8±0.2 mm). Except for two benchmark positions in PMMA-lung-PMMA (1 and 4),
which are close to the beam edge, all range differences between the two measurements are
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smaller than 1.7 mm. On averadge method C calculates the best agreement between the
depth profiles for shifts of about 0.7±0.2 mm. In conclusion, we found that the reproducibil-
ity of the measured PET range is of the order of 1 mm in standard deviation.
4.3.2 Consistency of the measured PET signal
In order to evaluate the consistency of the PET signal, we compared activity depth profiles
within identical material arrangements, but at different positions within the irradiation field.
For each position, we used three different areas a), b) and c) over which the signal was av-
eraged. Examples of the measured depth profiles, and the deduced beam ranges thereafter,
are shown in Figure 4.4 for three benchmark positions per layer (marked with ∗ in Figure
4.2c). These positions were selected so that two of them would be at the same distance
from the scanning field center, while the third would be at a larger distance. Figure 4.4
illustrates the measured range dependence on two factors: radial distance (‘global noise’)
and average area (‘local noise’). On the right, extracted ranges at 20% (method A) and 50%
(method B) of the last fall-off for each depth profile position and each average area are shown.
The depth profiles for each material arrangement show variations in their absolute values,
but are very similar in the fall-off region. For the case of the PMMA-air-PMMA layer, the
ranges for all three benchmark positions agree within 1.7 mm for method A, and within
0.9 mm for method B. The ranges of the two benchmark positions at the same distance
to the origin show a slightly enhanced similarity as opposed to non-equidistant benchmark
positions. This could be an indication for a weak dependence of the measured PET signal
on the radial position within the scanning field.
In the case of the PMMA-bone-PMMA layer, the ranges show larger variations than in
the previous geometry. For method A as well as for method B, the ranges for all three bench-
mark positions agree within 2.5 mm. Here only for method B a slightly enhanced agreement
in the ranges of equidistant benchmark positions is noticeable.
When the beam traverses the PMMA-lung-PMMA layer, the ranges demonstrate even
larger variations than those seen for the other geometries. For method A, the ranges for all
three benchmark positions agree within 1.8 mm, whereas they vary by 3.8 mm for method B.
Here no enhanced similarity of ranges at benchmark positions located at the same distance
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Fig. 4.4: Left: Activation depth profiles at 3 different positions (numbers in the legend refer to
positions in Figure 4.2c)) through PMMA-air/bone/lung-PMMA (the red and blue curves
correspond to benchmark positions that have the same distance to the scanning field
origin, while the yellow curve refers to a position at a larger distance). The signal was
averaged over three different areas (dotted a)/dashed b)/solid c)). Right: Ranges at the
20%(dashed stars) and the 50%(filled stars) fall-off position for the three measurement
positions and the three different averaging areas.
from the scanning field origin was observed.
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Table 4.4 summarizes the results for all benchmark positions shown in Figure 4.2c). By
analyzing depth profiles averaged over different areas perpendicular to the profile direction
we observed that the measured PET range is relatively insensitive to ’local noise’ (<1 mm
difference in range). Only a weak correlation of the measured range to the radial position in
the scanning field was observed.
The standard deviation of the 20% range (method A) averaged over all benchmark posi-
tions is about 1 mm, 1.3 mm and 1.5 mm for the PMMA-air-PMMA, PMMA-bone-PMMA
and PMMA-lung-PMMA layers, respectively. The corresponding numbers for the 50% range
(method B) are 1.1 mm, 1.1 mm and 0.6 mm, respectively. The largest deviations from the
mean range (up to 2.5 mm) occur mainly for benchmark positions at the beam edge and
therefore also at the edge of the FOV of the PET scanner, see Figure 4.5. In addition to
the position of these depth profiles also beam divergence effects could explain these large
variations.
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Fig. 4.5: Variations of the measured ranges in each material arrangement for average area a).
Consistency of PET signal as derived from measurement and MC simulations
In the clinical application of PET range verification measured activation profiles are com-
pared with MC simulated activation profiles. Thus not the variations of the measured ranges
but the variation in the differences between measured and simulated ranges are a norm for
the consistency of the PET/CT range verification method. Also variations of the measured
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50% range (method A) [mm] 20% range (method B) [mm]
Position a) b) c) a) b) c)
PMMA-air-PMMA
1 55.42 54.57* 46.18* 62.85 62.8 61.46
2 55.74 55.47 54.78 63.7 63.7 63.38
3 56.01 56.1 56.11 64.32 64.31 64.24
4 57.71 57.64 57.65 64.45 64.44 64.49
5 56.55 56.41 56.74 63.94 63.91 64.01
6 56.47 56.46 56.51 64.09 64.07 63.97
7 58.43 58.42 58.22 65.57 65.55 65.34
8 54.94 55.14 56.4 65.02 65.06 65.11
Mean ± SD 56.4±1.1 56.5±1.1 56.7±1.0 64.2±0.8 64.2±0.8 64.0±1.1
PMMA-lung-PMMA
1 -3.1 -3.01 -2.6 8.58 8.59 8.69
2 0.89 0.72 0.08 9.72 9.79 9.95
3 -0.45 -0.51 -1.12 11.43 11.46 11.08
4 0.57 0.85 1.39 11.73 11.76 12.18
5 -0.53 -0.51 -0.66 12.1 12.03 11.61
Mean ± SD -0.5±1.2 -0.5±1.1 -0.6±1.0 10.6±1.4 10.7±1.3 10.7±1.3
PMMA-bone-PMMA
1 47.1 47.12 46.63 55.65 55.63 55.53
2 47.07 47.08 47.05 56.84 56.86 56.76
3 47.93 48.3 48.39 59.34 59.3 59.06
Mean ± SD 47.4±0.4 47.5±0.6 47.4±0.8 57.3±1.5 57.3±1.5 57.1±1.5
Tab. 4.4: 20% and 50% fall-off ranges at all benchmark positions in Figure 4.2c) for three different
averaging areas a), b) and c). The average range (and one standard deviation) over all
positions in a layer is also given. (Data denoted by an asterisk were excluded from the
analysis due to the depth profile position close to the irradiation field margin.)
ranges due to divergence effects should be corrected by subtracting the corresponding MC
simulated PET ranges. However, variations due to benchmark positions close to the FOV
in the PET scanner will remain.
Figure 4.6 shows the variations of the differences between measured and simulated PET
44
4.3. RESULTS
range, normalized to the mean difference for method A and B (left) and method C (right).
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Fig. 4.6: Left: Differences at the 20% and 50% fall off position between measured and simulated
PET range normalized to the mean difference for the 16 benchmark positions shown in
Figure 4.2c). Right: Normalized difference between measured and simulated PET range
analyzed with the shift method.
Table 4.5 shows the standard deviation of the differences between simulated and mea-
sured range for all three methods. The shift analysis gives standard deviations of 0.9 mm,
0.6 mm and 0.5 mm for PMMA-air-PMMA, PMMA-bone-PMMA and PMMA-lung-PMMA,
respectively.
We conclude that the consistency of the PET/CT range verification method is of the
order of 1 mm in standard deviation, i.e. of the same order as the reproducibility of the
range measurement.
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Standard deviation of the differences
between MC and Measurement [mm]
50% range 20% range Shift
(method A) (method B) (method C)
PMMA-air-PMMA
0.9 0.7 0.9
PMMA-lung-PMMA
1.2 0.6 0.6
PMMA-bone-PMMA
0.3 0.7 0.5
Tab. 4.5: Standard deviations of the differences between simulated and measured ranges at all
benchmark positions in Figure 4.2c) and for all range verification methods (A-C).
4.3.3 Sensitivity of the measured PET signal to tissue inhomogeneities
We compared measured and MC simulated activity depth profiles through tissue interfaces
with different angles to the beam direction (blue: 6◦, red: 0◦). The irradiated geometries
are shown schematically in Figure 4.7.
Fig. 4.7: Tissue interfaces placed at 6◦ (blue) or 0◦ (red) with respect to the beam direction.
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We calculated the range difference for the two interface angles as
∆Rmeas = Rmeas(0
◦)−Rmeas(6◦) (4.1)
∆RMC = RMC(0
◦)−RMC(6◦) (4.2)
for the measured and simulated depth profiles, respectively, where R(0◦ and R(6◦ are the
ranges for the 0◦ and 6◦ interfaces, as shown in Figure 4.7. The range calculation was done
using methods A, B and C, as described above. Figure 4.8 shows the measured (left) and
simulated (right) activity depth profiles. Table 4.6 summarizes the measured and MC pre-
dicted range differences at the 20% and 50% fall-off position and as calculated by the shift
method.
20% range 50% range shift
(method A) (method B) (method C)
lung/air interface
∆Rmeas[mm] 0.47 0.22 0.65
∆RMC [mm] -1.20 -1.31 -1.30
∆Rmeas −∆RMC [mm] 1.67 1.53 1.95
bone/air interface
∆Rmeas[mm] -2.82 -3.48 -3.24
∆RMC [mm] -7.94 -2.64 -2.59
∆Rmeas −∆RMC [mm] 5.12 0.84 0.65
bone/lung interface
∆Rmeas[mm] -5.74 -0.03 -3.89
∆RMC [mm] -6.56 -0.92 -2.59
∆Rmeas −∆RMC [mm] 0.82 0.89 1.30
Tab. 4.6: Measured and simulated range differences for depth profiles through tissue interfaces
placed at 6◦ or 0◦ with respect to the beam direction. In addition the differences of the
measured and simulated differences are given.
Since air and lung tissue exhibit relatively small density differences, we did not expect
to observe a significant range difference for a beam traveling though a 6◦ or a 0◦ air/lung
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Fig. 4.8: Measured (left) and simulated (right) activity depth profiles through tissue interfaces
placed at 6◦ (blue) or 0◦ (red) with respect to the beam direction. The interfaces are
lung/air (top), bone/air (middle) and bone/lung (bottom).
interface. The measured and simulated range differences are up to 1.3 mm (Table 4.6) and
agree within 1.7 mm for the 50% fall-off position (method A), within 1.5 mm for the 20%
fall of position (method B) and within 2 mm for the shift analysis (method C).
We found significantly larger range differences (up to 7.9 mm) for the bone/air interface.
This is due to the density difference of air and bone tissue. Measurement and simulation
agree within 5.1 mm at the 50% fall-off position, within 0.8 mm at the 20% fall-off position
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and within 0.7 mm for the shift analysis.
The results for the bone/lung interface are similar to the bone/air results. This is due to
the relative small differences in density between air and lung compared to bone. Measure-
ment and MC prediction agree within 0.8 mm for method A, within 0.9 mm for method B
and within 1.3 mm for method C.
For all three tissue interfaces, the agreement between measured and MC predicted range
differences from the shift analysis is within 2 mm. MC simulated dose distributions are
considered as the most precise calculation of the delivered dose [And91] and hence the most
precise prediction of the resulting PET activation compared to for example the filtering ap-
proach described in [Par06]. However, in this phantom study comparisons of MC simulated
depth profiles through different angled interfaces are especially sensitive to the PVE. As men-
tioned above, the PEV is less pronounced in patient calculations and thus the already very
satisfying agreement between measured and MC predicted range differences in our phantom
study is a demonstration of the high sensitivity of the PET/CT range verification method.
This phantom study indicates the feasibility of PET/CT treatment verification to detect
small range variations in the presence of complex tissue inhomogeneities.
4.4 Discussion
This phantom study concentrates on the physical potential of PET/CT range verification
for proton treatments. The standard deviation of 1.0 mm of range differences between two
independent measurements and the standard deviation of 1.0 mm of range variations within
one measurement show the good reproducibility and the consistency of the measured PET
activation signal. However, range differences up to 2.6 mm between two measurements, as
well as global range variations up to 2.6 mm within one measurement can occur in a phantom
measurement. Those large deviations only occur at the beam edge or at positions on the
edges of the FOV in the PET scanner and therefore should be of minor importance in a
typical patient case. Range verification in the center of a typical patient field that usually
does not exceed a diameter of 10 cm and is well positioned in the center of the FOV of the
scanner, should have a physical accuracy of 1 mm.
Results of the low-statistics analysis were found to be in the same order of magnitude
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as the presented results for the reproducibility, the consistency and the sensitivity. Typical
dose per day for a patient treatment are 1-3 Gy(RBE). Results concerning the physical po-
tential of the method achieved in this phantom study are applicable for the patient routine
performed at our facility and the more in clinical practice at facilities where reduced delay
times between treatment and PET/CT scan are feasible.
This phantom study indicates the physical potential for millimeter accuracy in PET range
verification of the dose delivered in proton irradiation by commercially available PET/CT
scanners like the Biograph 64 PET/CT scanner.
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5.1 Introduction
The clinical pilot study [Par07b] investigated the feasibility of PET/CT treatment veri-
fication in a small population of 9 patients for tumor sites including head-and-neck (4),
paraspinal (3), orbit (1) and eye (1). It was shown that the beam range could be verified
within an accuracy of 1-2 mm in low perfused bony structures of head and neck patients
for which an accurate co-registration of predominate bony anatomy (skull) was possible. At
other positions and for other tumor sites, however, millimeter-accurate range verification
failed. The most likely reason was attributed to limitations due to washout and rigid co-
registration as well as motion uncertainties in the prolonged scan time of 30 min.
To employ PET/CT range verification clinically, it is crucial to know whether disagree-
ments between measured and calculated activity reflect errors in the treatment planning /
delivery or whether they are caused by inherent limitations of the method. Therefore, the
present study emphasizes the qualitative and quantitative specification of inherent challenges
of oﬄine PET/CT imaging for a larger population of patients and tumor sites. The aim is
to identify possible technological and methodological improvements, to allow for a wider
applicability of PET/CT range verification. A systematic data analysis was performed on a
large set of patients having a variety of tumor locations including head, spine and abdomino
pelvic. The following aspects are addressed:
• Restrictions on the accuracy of the oﬄine PET/CT range verification method due to
biological washout processes: Range verification ability is compared at positions where
the proton beam ranged out in bone and at positions where the beam ranged out in
well-perfused tissue.
• Effects on the accuracy of the oﬄine PET/CT verification method due to patient
motion: Lateral agreement between measured and simulated activity distributions for
tumors in the thorax and abdomen are compared to the lateral conformity in head and
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neck tumor cases.
• Uncertainties in the MC-simulated activity distributions due to the restricted correla-
tion in the mapping of HU to elemental compositions and washout characteristics: HU
domains for different organs in the abdomen and pelvis are determined to investigate
whether the HU mapping is sufficiently correlative to assign organ specific elemental
compositions and washout characteristics in the MC simulations. To test the influ-
ence of uncertainties, MC simulations for different HU mappings are performed and
compared.
• PET/CT range verification ability with respect to the tumor location: Patients were
grouped and average absolute range deviations for different tumor locations were calcu-
lated. Site-specific challenges in addition to the three factors listed above are evaluated
and an importance factor, indicating the degree of limitation on the PET/CT range
verification method at this tumor location, is introduced for each aspect.
5.2 Methods
For 23 patients (9 patient data sets were acquired before [Par07b], 14 within the framework
of this work) with tumors in the cranial base, spine, sacrum, prostrate and orbit an oﬄine
PET/CT scan after proton radiotherapy was performed at MGH. Table 3.1 gives detailed
information on the tumor site, the dose per field, the delay between irradiation and imaging
and the number of fields delivered in each patient at the day of the PET/CT scan. Table 5.1
gives an overview of the patient subgroups used for data analysis in the following sections.
The clinical protocol used is described in section 3.3.1.
Validation of the delivered treatment was achieved by comparing the measured activity
distribution with corresponding MC-simulated distributions, that were based on the treat-
ment plan, the planning CT data and the time course of irradiation and imaging, as described
in section 3.2.1. Data analysis was performed with methods described in section 3.4.
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# patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14
clinical pilot study [Par07b] X X X X X X X X X
5.3.1 First glance 2D X X X X X X X
5.3.2 First glance 1D X X X X X X
5.4.1 Reproducibility
5.4.2 Biological washout processes X X
5.4.3 Motion X X X X X X X X
5.4.4 Simulation uncertainties X X
5.4.5 Tumor site specific challenges X X X
5.4.6 Particular beneficial tumor sites X X X
# patient 15 16 17 18 19 20 21 22 22§ 23 23§ total
clinical pilot study [Par07b] 9
5.3.1 First glance 2D X X X X X X X 14
5.3.2 First glance 1D X X X X X 11
5.4.1 Reproducibility X X 1
5.4.2 Biological washout processes X X X X 6
5.4.3 Motion X X X X X X 14
5.4.4 Simulation uncertainties 2
5.4.5 Tumor site specific challenges X X X 6
5.4.6 Particular beneficial tumor sites X X X X X X X X X 10
Tab. 5.1: Overview about patient subgroups used for data analysis in the following sections (§:
Repeated PET/CT data acquisition)
5.3 Results I: Qualitative analysis of the feasibility of oﬄine in vivo
PET/CT range verification
5.3.1 2D - Gamma index analysis
Comparison of 2D color-wash images of measured and MC-simulated activity distributions
shows impressive qualitative similarity in most cases. However, a quantitative judgment
of the agreement of the two distributions based on color-wash images is difficult. More
precise information about the agreement in the absolute values of the distribution can be
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obtained from difference plots. Since the main interest of PET/CT imaging lies in a spatial
verification of the delivered dose distribution, a gamma index analysis gives more valuable
information. It allows to simultaneously evaluate the absolute and the spatial agreement of
the MC-simulated and measured activity distributions.
To perform a meaningful gamma index analysis reasonable absolute values and spatial
pass-fail criteria have to be established. Histograms for the coronal, transversal and sagittal
slice through the isocenter were calculated for 14 patients. In these histograms the absolute
difference in activation at each position as well as the distance to the nearest point with the
same activation (Figure 5.1) were evaluated.
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Fig. 5.1: Evaluation of variations in the absolute values (left) and spatial agreement (right) in the
coronal, transversal and sagittal cut through the isocenter for 14 patients (2 spine (thin
green), 6 head (thin red) and 6 abdominal pelvic (thin blue) tumor sites. Thick lines give
mean values for each of the three tumor site groups).
The left graph in Figure 5.1 illustrates that approximately 75% of the MC-simulated and
measured activity distribution show less than 45% variation in their absolute value. Like-
wise, 75% of the distribution shows a 100% absolute agreement within 3 mm periphery (right
graph of Figure 5.1). The average agreement of the MC-simulated and measured activity
distribution is thus within 45% of the absolute values of activation and within 3 mm spa-
tially. Hence 45% and 3 mm are reasonable cutoff values for a meaningful gamma index
analysis of activity distributions.
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The diversification into different tumor sites (head, spine, abdomino pelvic) in Figure
5.1 illustrates that the mean variation in the absolute values and the mean distances to
agreement are different, for different tumor locations. In the following sections, challenges of
oﬄine PET/CT range verification will be analyzed with respect to different tumor locations.
In section 5.4.5, site-specific weighting factors will be assigned to summarize which patient
groups can benefit most from the approach.
Besides the dependency of the absolute and the distance to agreement on the tumor site,
also the dependency on (i) the number of given treatment fields and (ii) the total dose on the
day of imaging, (iii) the delay between irradiation and imaging and (iv) the imaging planes
was evaluated. For the six head patients analyzed before, Figure 5.2 shows the evaluation
of variations in the absolute values and the spatial agreement with respect to the possible
dependencies.
Figure 5.2 indicates a marginal dependency of the absolute and spatial agreement on the
number of given treatment fields as well as on the imaging plane. The agreement between
measured and simulated activity distributions seems to be slightly improved for patients that
received two treatment fields at the day of imaging. An improved agreement is also recog-
nizable in transversal and frontal imaging planes. On the contrary, no dependency on the
total dose on the day of imaging or the delay between irradiation and imaging is apparent.
However, an analysis on a population of only six patients is not statistically sufficient to rule
out such dependencies.
5.3.2 1D - analysis
To explore the range verification ability of PET/CT imaging, simulated and measured activ-
ity depth profiles at a number of positions in each patient and for each treatment field were
evaluated with method A, B and C (as described in section 3.4.2). Profile positions were
chosen through the isocenter as well as in a raster of 1.5 cm (and 2 cm, 3 cm, 4.5 cm and 6
cm depending on the field size) in the orthogonal planes through the isocenter as illustrated
in Figure 5.3.
Figure 5.3 shows a percental occurrence of absolute range deviation between MC sim-
ulation and measurement. For an analysis at approximately 87 random positions mean
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Fig. 5.2: Absolute (left) and spatial (right) agreement of measured and simulated activity distribu-
tion in patients with tumors in the head with respect to (i) the number of given treatment
field and (ii) the total dose on the day of imaging, (iii) the delay between irradiation and
imaging and (iv) the imaging planes.
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Fig. 5.3: Left: Illustration of the chosen profile positions grid in an exemplary head patient, Mid-
dle: %-occurrence of absolute range deviations between simulated and measured activity
profiles in a population of 11 patients for method A, B and C. Right: Range deviations
calculated by the shift method shown for different tumor locations (spine: 20, head: 40, ab-
dominopelvic: 33 positions). Mean absolute deviation for spine, head and abdominopelvic
patients are given in green, red and blue, respectively.
variations are 5.6 mm, 4.0 mm and 3.6 mm for method A, B and C, respectively. The worse
outcome for method A is explainable by the influence of statistical noise and modeling un-
certainties, as discussed in section 3.4.2.
Range deviations, separately calculated by the shift method for different tumor locations,
show absolute mean values of 1.5 mm, 3.4 mm and 5.2 mm for tumors in the spine, head
and abdomino pelvic region, respectively. As in the 2D analysis, this illustrates that the
agreement between simulation and measurement is best for tumor locations in the spine,
and worse for tumor locations in the abdomino pelvic. For the observed range deviations
a systematic analysis of the underlying causes is presented in the next section. There, we
try to distinguish, whether these range deviations reflect errors during the treatment plan-
ning/delivery or whether they were caused by inherent challenges of the method. After
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discussing each involved effect individually, we will summarize the results in section 5.4.5
and draw conclusions about the dependency of the agreement between the simulated and
measured activity distribution on the tumor location.
5.4 Results II: Quantification of oﬄine in vivo PET/CT range verification
ability under different perspectives
5.4.1 Reproducibility
Before going into a systematic analysis of different challenging factors of the method, its
technical limitations are evaluated. Phantom studies, as well as the first clinical pilot study
[Par07a, Par07b], have demonstrated the feasibility of post-radiation PET/CT for in vivo
treatment verification. In the previous section 4.3.1 PET images from two independent mea-
surements were compared. The reproducibility of the measured PET range in a phantom
geometry was found to be within 1 mm standard deviation. However, in vivo patient PET
measurements are additionally challenged by blood perfusion, variations in the tissue com-
position, motion, and co-registration uncertainties.
To reveal technical limitations, such as the reproducibility for in vivo measurements, ac-
tivity distributions from two independent data acquisitions of the same treatment fraction
given at two different days, separated by one week, were compared in one patient (#22).
Images of the first repeated patient scan done so far are shown in Figure 5.4. The patient
received one right-anterior treatment field of 2.5 Gy(RBE) to a tumor location in the C-spine
at both days of PET/CT imaging. The comparison of the upper and lower row in Figure
5.4 demonstrates the excellent reproducibility of the characteristics in the measured PET
distribution.
The differences in the absolute values of the two PET measurements are up to 30%. These
differences are not due to differences in the time course of the two measurements. MC simu-
lations show that the effect of different time courses at most 3%. The differences seen in the
measured activity distributions rather reflect statistical errors, variations in the elemental
composition and the biological washout processes at different treatment days.
Range deviations between the two PET/CT scans were evaluated at 18 positions selected
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Fig. 5.4: Transversal, coronal and sagittal slice through the isocenter of the measured activity dis-
tribution. The first row shows images from the first scan. In the second row corresponding
images from the second data acquisition can be seen.
within the treatment field as illustrated in the left of Figure 5.5. The middle graph in Figure
5.5 shows that at 95% of the positions the activity ranges agree within 3 mm for metod
C. According to the right graph in Figure 5.5 the reproducibility of in vivo measured PET
ranges is of the order of 1 mm in standard deviation. Since a single repetition of the irradi-
ation and PET scan in only one patient cannot statistically ascertain the reproducibility, a
study about repeated PET/CT scans in a larger patient population is under way. However,
these data confirm the technical feasibility of in vivo range verification with commercially
available PET/CT scanners for proton irradiation therapy.
5.4.2 Biological washout processes
For 6 patients ranges were verified at positions where the proton beam ended in bone (case
i) as well as at positions where the beam stopped in well-perfused tissue to investigate the
influence of the biological washout on the accuracy of the method. For well-perfused tissue
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Fig. 5.5: Left: Profile positions. Middle: %-occurrence of absolute range deviations between two
PET/CT scans. Right: Range deviations at each position. The mean absolute range
deviation evaluated with the shift method was 1.14 mm.
it was distinguished whether the last maximum of the activity distribution was located in
bone (case ii) or in soft tissue (case iii). Examples for all three cases are shown in Figure 5.6.
The analysis was exclusively done for patients with tumors in the head and neck region that
enable a very good immobilization during the 30 min of PET scan. Head and Neck tumor
locations also provide a relatively rigid target geometry. Hence the influence of limiting fac-
tors such as patient motion (discussed in section 5.4.3) and image co-registration (discussed
in section 5.4.5) were minimized.
Absolute mean deviation between measured and simulated activity range for all three
cases (i, ii and iii) at the 50% (20%) position in the last fall-off region (method A (B)) as
well as evaluated by the shift method (method C) are given in Table 5.2. For case (i) all three
methods show a mean agreement of ranges within 2.5 mm. For case (ii) the shift method
calculates a mean agreement within 2.2 mm, while a pointwise mm-accurate range verifica-
tion seems to fail. For case (iii) all methods of analysis give relatively large absolute mean
deviation between MC-simulated and measured activity ranges. This confirms that oﬄine
PET/CT scans permit mm-accurate range verification only at limited positions within the
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Fig. 5.6: Simulated (first row) and measured (second row) PET distributions demonstrating the
following three cases: i) The distal activity fall-off is placed in bone (first column), ii)
The distal activity fall-off is placed in soft tissue with the last maximum in bone (second
column) and iii) The distal activity fall-off as well as the last maximum are placed in soft
tissue (third column). The third row shows profiles at positions marked by white the lines
above. The red arrows denote the beam direction.
treatment field, mainly in well-coregistered bony structures [Par07b].
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Mean agreement between measured and
number simulated range [mm]
of pointwise verification shift verification
profiles 50% 20%
bone (i) 25 2.5 1.2 2.4
bone/soft tissue (ii) 25 3.2 8.1 2.2
soft tissue (iii) 30 6.8 3.9 4.3
Tab. 5.2: Mean agreement between simulated and measured activity range for case i-iii. The range
verification was done point wise at the 50% and 20% position in the last fall-off region as
well as with the shift method.
Despite the good mean agreement between measured and simulated activity distribution
in bone (case (i)), discrepancies up to 6.6 mm (3.6 mm) can occur at the 50% (20%) fall-
off position. For some positions in bone the shift method even showed deviations larger
than 5 mm. However, at most of the positions in bone, where the shift method gave devia-
tions larger than the mean deviation, a failure of delivering the planned range could not be
proven. Variations in the absolute values of measured and simulated activity distribution,
degradations in the measured activity distribution due to activity fractions from different
overlapping treatment fields, or a coarse voxel dimension in profile direction were found to
be responsible for these discrepancies. These examples show that a ‘blind’ range verification
by PET/CT measurements is questionable. Positions where discrepancies between planned
and delivered range are detected have to be carefully investigated further to rule out other
explanations for the deviation.
In soft tissue point wise range verification turned out to impractical due to the degrada-
tion of the measured activity distribution by blood perfusion. Point wise range verification
via PET/CT measurements relies on a good landmark as well as absolute agreement between
measured and simulated activity distribution. The shift range verification is more robust
for spatial variations in the activity distribution and relies on an overall agreement of the
characteristic of two distributions. The shift method showed the potential of range verifica-
tion within 4.3 mm in soft tissue (case (iii)) and even within 2.2 mm if the last maximum
of the activity distribution lay in bone (case (ii)). However, for 27% (33%) of the positions
in soft tissue for case (ii) (case (iii)) the shift method gave deviations larger than ±5 mm.
In soft tissue it is even more complex to distinguish reasons for these deviations. Therefore,
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reliable range verification within 1-5 mm in soft tissue (case (iii)) by oﬄine PET/CT scans
was found to be infeasible.
Biological washout effects limit the area per treatment field where range verification is
possible. To overcome this problem, better models of the washout processes and more robust
analyzing tools are needed. Also shorter delay times between irradiation and PET imaging
would minimize the washout of the produced β+-emitters by blood perfusion [Par08]. A
detailed discussion of the work in progress concerning these possible enhancements of the
PET/CT range verification approach are given in section 7.1 and 7.2.
5.4.3 Motion
Patient motion during the 30 minutes of data acquisition at the PET/CT results in a blur-
ring of the measured activity distribution. To investigate the magnitude of blurring, lateral
conformity between measured and simulated activity was analyzed in 14 patients. Examples
of 6 patients can be seen in Figure 5.7. The extent of blurring can be especially well deter-
mined if the lateral fall-off takes place in bone tissue (see positions marked by a red arrows
in Figure 5.7), because washout of the activity due to blood perfusion will be minimized there.
Lateral blurring in abdomino pelvic tumor sites ranges up to 30 mm, compared to confor-
mity for head and neck tumor sites ranging up to 5 mm. Lateral blurring is dominant in the
anterior-posterior direction, reflecting the breathing motion during the 30min of PET scan.
The breathing motion prevents range verification especially for anterior and/or poste-
rior treatment fields in the abdomino pelvic region, as illustrated in the left of Figure 5.8.
For superior/inferior treatment fields, anterior-posterior breathing motion disables spatially
dissolved range verification by PET/CT imaging. However, a range verification would be
possible, in case of a uniform range per field. This situation is illustrated in the middle two
pictures in Figure 5.8. Since the range varies within most treatment beams to match the
distal edge of the tumor, anterior-posterior patient motion also affects the range verification
ability for any beam direction, as seen in the right of Figure 5.8. Thus unavoidable patient
motion during the PET data acquisition excludes most tumor sites in the thoracic cavity
from mm-accurate range verification via the current 3D PET/CT imaging strategy.
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Fig. 5.7: Lateral conformity between MC-simulated and measured activity distribution for three
exemplary abdomino pelvic (three images on the left) and three exemplary head (three
images on the right) patient cases (Green scale with ticks in 1 cm intervals, red arrows
point to positions where the lateral fall of occurs in bone).
5.4.4 Simulation uncertainties
Treatment verification is achieved by comparing measured with MC simulated activity dis-
tributions. The accuracy of the MC simulated activity distribution depends mainly on the
precise knowledge of the elemental composition and the washout characteristics of the under-
lying tissues. Tissue characteristics are assigned by means of HU from the patient planning
CT. The main challenges of this approach are discussed in the following subsections:
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Fig. 5.8: Influence of anterior-posterior breathing motion on the range verification ability of anterior
treatment fields (left), superior treatment beams with uniform range (middle) and superior
treatment fields with varying range (right).
• To investigate the ability of tissue identification by means of CT data, HU values for
different organs were evaluated. This way it was investigate whether a HU mapping
is sufficiently correlative to assign organ specific elemental compositions and washout
characteristics.
• To investigate the sensitivity of the MC simulation on the HU mapping, activity dis-
tributions calculated with different HU maps were compared. Furthermore, MC sim-
ulations using different washout models were compared.
Correlativity of HU mapping
The difficulty of tissue identification increases with an increasing variety of tissues present
in the tumor proximity. The more different tissues are present the less correlative is the con-
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version from HU into specific tissues. The HU analysis for a head patient, displayed on the
left of Figure 5.9, shows clearly separated HU domains for fat, brain and bone tissue. The
HU analysis for an abdomino pelvic patient, displayed on the right of Figure 5.9, however,
shows overlapping HU domains. HU for bone marrow (red framed region) are between -20
and 110, which is in the same HU domain assigned to soft tissue (blue framed region).
Fig. 5.9: HU analysis for an exemplary head patient (left) and an exemplary abdomino pelvic
patient (right).
Conversion of HU into mass density and elemental composition is currently based on a
segmentation of the CT scan into 26 materials sharing the same composition and a nominal
mean density for -1000 ≤ HU < 3060 [Par02, Par07a, Schn00]. For HU ≥ 3060 Titanium
is assigned [Par07a]. HU values between -20 and 120 are assigned to four materials with
elemental compositions given in Table 5.3. These materials accurately reflect soft tissues,
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but differ from the elemental composition of bone marrow, which is given in the last row of
Table 5.3.
HU H(%) C(%) N(%) O(%) Na(%) P(%) S(%) Cl(%) K(%)
-22 - 7 10.8 35.6 2.2 50.9 0.1 0.2 0.2
8 - 18 10.6 28.4 2.6 57.8 0.1 0.2 0.2 0.1
19 - 80 10.6 28.4 2.6 57.8 0.1 0.2 0.2 0.1
80-120 9.4 20.7 6.2 62.2 0.6 0.6 0.3
bone marrow 11.0 52.9 2.1 33.5 0.1
Tab. 5.3: Conversion of HU between -22 1nd 120 to elemental weights based on [Schn00]. The
elemental composition of bone marrow is given in the last row.
The abdomino pelvic patient example shows that the HU mapping is not sufficiently
correlative to assign organ specific elemental compositions and washout characteristics in the
MC simulations. A possible method to overcome the problem of overlapping HU domains
would be an assignment of elemental compositions and washout characteristics based on
manually delineated organ contours as proposed in [Par07b].
Sensitivity of the MC simulation on the HU mapping
The influence of different HU to elemental composition conversions and different washout
models on the range verification ability of the oﬄine PET/CT approach is investigated in
the abdomino pelvic patient example, studied in the previous section. Figure 5.10 shows a
comparison between MC simulated and measured activity in this patient. The MC simula-
tion was performed using the Schneider HU conversion and the washout modeling described
in section 3.2.1, which will be referred to as the ‘original’ parameters throughout this section.
It is noticeable that the measured activity distribution on the left is much more blurred
than the simulated one on the right. This is due to washout effects, motion and the need of
prostate patients to void their bladder between irradiation and imaging. These effects can
only roughly be taken into account in the simulation. Furthermore, one can clearly see an
underestimation of activity in bone marrow by the MC simulation. The low activation in
bone marrow in the simulated activity can be explained by the fractions of carbon assigned
to HU values between -20 and 110 by the Schneider conversion. While these fractions resam-
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Fig. 5.10: Comparison of a measured and MC simulated activity distribution in an abdomino pelvic
tumor site.
ple the composition of soft tissue, the fraction of carbon in bone marrow is underestimated
by almost 50%, as seen in Table 5.3. Since the main part of activation is produced through
the (p, pn) channel on 12C, the Schneider HU conversion results in an underestimation of
activity in bone marrow. Furthermore, HU between -22 and 110 are assigned to highly per-
fused tissue in the original washout model, which further increases the underestimation of
activation in bone marrow by the MC simulation.
Figure 5.11 shows a MC simulated activity distribution using (i) the original parameters
described in section 3.2.1(upper row), (ii) a different HU conversion (second row left) and
(iii) a different washout model (second row right). In the last row difference plots of the
original MC simulation and the two adjusted simulations can be seen, respectively. The ad-
justments in the HU conversion and the washout model were done with the goal of improving
the similarity between measured and simulated activity distribution, and in particular to re-
duce the differences in bone marrow areas. The HU to elemental composition conversion
was adjusted in a way that assured the same range in the dose distribution for a simulation
with and without adjustment. For HU domains between -22 and 120 the assigned elemental
composition was changed to the elemental composition of bone marrow, seen in the last row
of Table 5.3. To compensate the few mm range change in the dose distribution caused by
this new assignment, density correction factors were introduced. The original washout model
and the adjustments can be seen in table 5.4. A low perfusion domain was added for HU
between -22 and 120, associated with bone marrow.
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Fig. 5.11: MC simulated activity distribution using (i) the ‘original’ parameters described in section
3.2.1 (first row), (ii) an adjusted HU conversion (second row left) and (iii) an adjusted
washout model (second row right). In the last row, different plots of the respective
distributions can be seen.
The difference plots in figure 5.11 show that the absolute values in the MC simulated
β+-activity are very sensitive on the HU conversion and the washout model. Deviations of
up to 27% appear in MC simulated activity distribustions, using once the orginal and once
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Tab. 5.4: Original and adjusted parameters for the washout model used in the MC simulation (i)
and (iii).
the adjusted HU conversion. Deviations of up to 36% appear when using different washout
models. Thus, the deviation between measured and simulated activity of about 45% seen in
section 5.3.1 can be explained in large parts by the rough estimate of parameters in the MC
simulation.
The overall similarity between the measured and simulated activity distribution in this
patient example does not improve much, despite the adjustments in the HU conversion and
the washout modeling. One explanation is that the adjustment does not only affect specific
tissues, but entire HU domains associated with different tissues. While differences between
measured and simulated activity decrease in bone marrow, they increase for soft tissue. Be-
yond this problem, that will be apparent for all parameter assignments based on HU, it is
also noticeable that even with adjustments there are big differences in the absolute activity
values between measurement and simulation in bone marrow. This shows that the parame-
ters established for bone marrow are imprecise, and that parameters for activity simulation
in abdomino pelvic tumor sites need to be further investigated and adjusted.
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Adjustments in the HU conversion or the washout modeling can also affect the range
verification. Figure 5.12 shows depth profiles of the planing CT, the simulated dose, and the
measured/simulated activity distributions through the isocenter. Profiles of the simulated
distributions are displayed using the original, as well as the adjusted parameters. One can
nicely see that the dose profiles almost perfectly overlay each other, no matter which HU
conversion was used in the MC simulation. On the contrary, major variations are noticeable
in the activity profiles. Table 5.5 shows range deviations in the activity profiles for the use of
different parameters in the MC simulation. Adjustment of the parameters can cause range
differences in the simulated activity distribution of about 1.8 mm.
Fig. 5.12: Profiles of the planing CT, the simulated dose and the measured/simulated activity
distributions: Profiles of the simulated distributions are displayed using the original as
well as the adjusted parameters. Simulated dose profiles using different parameter sets
almost perfectly overlay each other.
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20% range 50% range shift
(method A) (method B) (method C)
Rorig.param. −Radj.HUconv.[mm] 1.80 2.41 1.81
Rorig.param. −Radj.washoutmodel[mm] 1.70 2.28 1.81
Tab. 5.5: Activity range differences caused by parameter changes in the MC simulation.
The previous analysis indicates that activity simulations are very sensitive to the HU
conversion and the washout models, contrary to dose simulations. Different parameters do
not only affect the absolute values of the simulated activity, but also the activity range. The
HU conversion and washout model described in section 3.2.1 were established for head/neck
and paraspnal tumor sites. For abdomino pelvic tumor sites careful adjustments have to be
made. Rough modeling of parameters can easily result in 30% uncertainty in the absolut
activity values, and 2 mm uncertainty in the activity range.
5.4.5 Tumor site specific challenges
In the previous sections, biological washout, motion, and uncertainties in the MC simulations
were discussed. They are the main challenging factors for the in vivo oﬄine PET/CT
approach and affect more or less all tumor sites. In addition to these three factors, there exist
conditions that compromise the PET/CT range verification approach only for a selection of
tumor sites:
Beam directions: Range verification via post treatment oﬄine PET/CT imaging is only
feasible for single beams, or for beams delivered nearly perpendicular to each other in
a single fraction. For opposed beams or for beams with small angles the distal edge in
the activity distribution is a result of protons from multiple beam directions. In these
beam configurations it is therefore difficult to achieve range verification separately for
each treatment field. Opposed beam directions are more likely in abdomino pelvic
treatment areas (sacrum, prostate) than in head and neck tumor patients. Patients
#12, #15, #18 (see table 3.1) are examples, in which PET/CT range verification failed
due to the beam arrangement.
CT fusion: Differences in the positioning of the patient during treatment and during PET
imaging are taken into account by fusing the planning CT and the PET CT. For
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patients with tumors in the eye, a CT of only a very small area around the target
is obtained for treatment planning. This does not allow fusion with the PET CT
[Par07b]. Patient #7 (see table 3.1) is an example in which CT fusion was not feasible.
In this case correct alignment of the measured and simulated activity distribution was
based on the matching of fiducial markers. This procedure is expected to introduce
lager uncertainties than the usual fusion of CT images. The accuracy of the CT fusion
depends on the rigidity of the patient geometry. Head and neck tumors provide a
higher degree of rigidness than abdomino pelvic tumor sites. Here the position of the
legs for example can influence the whole geometry of the tumor area.
Organ position: For prostate tumors, a site-specific limitation is the need of the patients
to void their bladder between treatment and imaging. This changes the geometry for
the PET/CT imaging, as compared to the situation during treatment. The change in
geometry appears in a way that cannot be taken into account by the rigid CT fusion,
and only with difficulty by means of non-rigid registration. In the scope of this study,
two patients with tumors in the prostate (patient #14 and #16) have been imaged.
Also for patients that cannot be immobilized in the same way during PET/CT imaging
and treatment, such as eye patients (patient #7), organ motion is a challenge.
Table 5.6 summarizes all previous results by assigning tumor site-specific weighting fac-
tors to all the different challenges of PET/CT range verification. A value of 1/green means
‘this site is only slightly influenced by this factor’, 2/orange means ‘this site is influenced
by this factor, but there are ways to minimize the influence’ and 3/red means ‘this site is
highly influenced by this factor and also improvements of the method would not resolve this
influence’. Note that the assigned factors partly based on very limited patient cases. Table
5.6 is intended as a guideline to estimate the benefit of oﬄine PET/CT range verification
for different patient groups.
The cumulative weighting factors in the last row of table 5.6 reflect the result of mean
range deviations between measured and MC simulated activity distributions, broken down
for different tumor locations (Figure 5.3 right). The current oﬄine PET/CT range veri-
fication approach is a promising tool for head and neck patients, while it currently faces
insuperable limitations for abdomino pelvic tumor sites.
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Spine 1 1 1 1 2 1 7
Head 2 1 1 2 1 1 8
Thorax 2 3 2 1 2 2 12
Eye 2 2 2 1 3 2 12
Abdomen 3 3 3 2 3 2 16
Prostate 3 3 3 3 3 3 18
Tab. 5.6: Tumor site-specific weighting factors for the different challenges of the PET/CT range
verification method.
5.4.6 Particularly promising patient groups for PET/CT range verification
Patients with tumors in the head and neck region
Current experience clearly emphasizes that patients with tumors in the head and neck region
can benefit most from oﬄine PET/CT range verification. The main limiting factor for head
tumor sites are biological washout processes. Efforts to develop better models for washout
processes are currently under way and are discussed in section 7.2. In section 7.1 the perfor-
mance of the PET/CT approach for shorter delay times is investigated. There the influence
of washout effects is compared for oﬄine and in-room PET measurement. In in-room data
acquisition there is almost no delay between irradiation and imaging and thus the influence
of washout processes is expected to be minimal.
Head and neck patients often combine very inhomogeneous tissue arrangements in the
beam path with tumor locations very close to critical structures. The good performance of
the PET/CT approach makes urgently needed range verification feasible for routinely use in
the near future.
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Patients with arteriovenous malformations (AVMs)
Patients with AVMs represent a special class within the group of head and neck patients.
AVM is a tangle of dilated blood vessels that disrupts normal blood flow in the brain. Prior
to radiotherapy treatment the patients obtain embolization - a deliberate obstruction of a
blood vessel with a specially designed glue. The ‘emboli’ formed by this agent plugs the
vessels of the AVM, reducing the size of the nidus and thereby creating a smaller target for
irradiation. However, the induced material causes major artifacts on the CT due to its por-
tion of tantalum. For treatment planing specific density measurements of the glue used are
done. The target area is delineated manually based on MRI images to assure an irradiation,
as precise as possible. However, the irradiation of AVM patients implies more uncertainties
than treatments of other head tumor sites. PET/CT measurements could be used as an
additional quality assurance tool. Since most of the AVM patient treatments follow a hyper-
fractionated schedule, PET/CT measurement are especially promising. The high dose per
fraction (typically 8-16 Gy(RBE)) translates into enhanced image quality in the PET scan.
Delineation or density uncertainties can result in under or overshooting. Oﬄine PET/CT
measurements could be used to monitor these errors in dose in the first treatment fraction,
so that the second fractions could then be corrected accordingly.
Figure 5.13 shows images of an AVM patient receiving three treatment fields of a total
dose of 8 Gy(RBE). A right-posterior field was followed by a right-superior field and a left-
posterior field. The same treatment fraction was irradiated and imaged twice within one
week.
Artifacts caused by the tantalum portion of the inserted glue are apparent in the CT in
Figure 5.13. As in section 5.4.1, images from the repeated PET/CT data acquisition show
impressive similarity. After the first irradiation and PET data acquisition it was found that
the range of the right-superior field had been slightly underestimated. Therefore, it was
extended by 3 mm in the second irradiation and PET data acquisition. Figure 5.14 shows
activity range differences between the two data acquisitions for the right-superior treatment
beam.
Despite the 3 mm range adjustment in the second irradiation, the mean range difference
in the activity distributions of the right-superior treatment beam is 0.13 mm between the
two data acquisitions. There are various explanations, for why the range adjustment is not
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Fig. 5.13: Transversal, sagittal and coronal slice through the isocenter of the measured activity
distribution. The first row shows images from the first scan. In the second row the
corresponding images from the second data acquisition can be seen.
reflected in the activity measurements. First of all, the intended 3 mm adjustment could not
really have been delivered. A check of the error in the actually delivered ranges was done
in a water tank. Intended beam ranges of 10 cm and 10.3 cm were measured to be 10.06
cm and 10.22 cm when delivered. This gives an error of about ±0.8 mm in the delivery.
Thus the intended range adjustment of 3 mm could have shrunk to 1.2 mm when delivered.
Furthermore, the PET scanner measures the accumulated activity of all the treatment fields
delivered in one fraction. Thus the distal fall-off of the right-superior field is overlaid with
the lateral fall-off’s of the two posterior fields. Even so the beam range was changed in
the right-superior field, it could be that the corresponding edge in the activity distribution
remains the same because it is mainly determined by the two posterior fields. Finally, the
influence of washout effects could have blurred the activity distribution, so that the activity
range difference is not noticeable anymore.
PET/CT range verification is particular desired and promising in AVM patients. How-
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Fig. 5.14: Left: Profile positions. Middle: %-occurrence of absolute range deviations between two
PET/CT scans. Right: Range deviations at each position. The mean absolute range
deviation evaluated with the shift method was 0.125 mm.
ever, the previous discussion also shows particular challenges. On the one hand, the hyper
fractionated treatment schedule offers high doses per fraction and thus a good signal to noise
ratio. On the other hand, it creates the necessity to deliver multiple fields per fraction. Since
oﬄine PET scans only measure the accumulated activity, range verification for each field is
difficult to resolve.
Patients with metal implants
Dose calculation and treatment planning for patients with metal implants is challenging
for two reasons: First, pencil-beam algorithms have difficulty handling geometries including
metal regions. Secondly, CT artifacts impede accurate dose planning. Artifacts in the plan-
ning CT either cause dose undershoots or dose overshoots. The effects of artifacts are very
case dependent as addressed in [Ja¨k07]. Figure 5.15 shows a comparison between calculated
and measured activity distribution in a patient with metal implants. The PET measurement
confirmed that the overshoot in the simulated activity distribution had not actually been
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delivered.
Fig. 5.15: Comparison between calculated (left) and measured (right) activity distribution in a
patient with metal implants.
As seen in the example above, PET/CT measurements are capable of validating cor-
rect treatment delivery in the case of metal implants. Predicted over or undershoots can
be excluded by imaging the first treatment fraction. This way, PET/CT imaging can be
employed as a quality assurance tool for the successive treatment fractions. However mm-
accurate range verification fails in the presence of metal implants due to the attenuation
correction of the PET images, which is also affected by artifacts.
5.5 Discussion
Deviations of about 45% between the measured and MC simulated activity absolute values
could be seen in the qualitative analysis of section 5.3. Repeated PET/CT data acquisition,
as investigated in section 5.4.1, showed that measured activity values could only be repro-
duced within a 30% uncertainty. In section 5.4.4 it could be seen that different HU maps
and washout models can affect MC simulated activities up to 36%. These uncertainties in
the quantification of activity values show that the current PET/CT approach is not feasible
to verify absolute dose information. Improvements in the HU mapping based on a better
understanding of tissue compositions are needed. Furthermore, washout models have to
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be expanded. Precise space (i.e., tissue) and time-dependent weighting factors, especially
for tumor locations other than head and neck, have to be established. If at all, a verifi-
cation of absolute dose values is only possible for an assignment of elemental compositions
and washout characteristics based on manually delineated organ contours, as proposed in
[Par07b].
However, PET/CT imaging is a promising tool for range verification. Previous evalua-
tion of data coming from a well-balanced patient population allows a distinction between
limitations and conquerable challenges of the PET/CT range verification approach for each
considered tumor site. For head and neck tumor sites range verification within an accuracy
of 1-2 mm is feasible. The main limitation here is biological washout in soft tissues, which
degrades the measured activity distribution. In abdomino pelvic tumor sites, mm-accurate
oﬄine PET/CT range verification is currently not feasible. This is primarily due to patient
motion and complex tissue heterogeneities that introduce uncertainties in the MC simu-
lation. However, in this tumor location PET/CT imaging is usable for quality assurance.
Despite the uncertainties, wrong dose calculation due to CT artifacts can be falsified by PET
imaging. In abdomino pelvic patient cases that involve a lot of uncertainties, PET range
verification with an accuracy of currently 5-6 mm might be valuable.
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6. SUMMARY
Radiotherapy treatment with protons enjoys rising interest and importance with an increas-
ing number of clinical proton therapy facilities worldwide. In particular, for inoperable
tumors growing in close proximity to critical organs the high selectivity of protons has an
enormous potential benefit. Protons of a certain energy exhibit a specific range which de-
termines the position of the maximum dose delivery in the target. To make full use of this
superior characteristic, techniques are required that allow a millimeter precise monitoring of
the proton trajectory and especially the proton range. At present, PET imaging represents
the only feasible method for in vivo and noninvasive proton range verification.
In this thesis we mainly studied oﬄine PET/CT range verification. The measured activ-
ity signal is correlated but not directly proportional to the spatial pattern of the delivered
dose. Therapy control is achieved by comparing the measured activity distribution with a
prediction based on the treatment plan and the specific time course of the particular irradi-
ation. To employ oﬄine PET/CT range verification clinically, it is crucial to know whether
disagreements between measured and predicted activity maps reflect errors in the treatment
planning, calculation or delivery, or whether they are caused by inherent limitations of the
method.
It was found that the physical properties are provided to perform mm-accurate range veri-
fication by oﬄine PET/CT imaging, but that the approach faces several challenges in clinical
applications. Biological washout processes impede a range verification in well perfused tis-
sues, motion prevents mm-accurate results in abdominopelvic tumor sites, and limitations
in the MC simulation compromise the feasibility of the method for tumor regions with many
different tissues in close proximity. Furthermore, tumor site specific conditions like certain
beam direction configurations or destined patient positions limit the applicability of the
method. Thus the current approach allows 1-2 mm accurate range verification only at spe-
cific positions and for a limited patient subgroup.
6. SUMMARY
However, most of the challenges can be overcome or at least constricted. The problem of
biological washout, for example, could be tackled by on line PET imaging. CTP imaging
could help to develop better models to account for those perfusion processes in the MC
simulation. 4D-PET (gated PET) could help to solve the problem of motion. Detailed con-
touring of structures in the CT and corresponding assignment of tissue parameters could
help to overcome limitations in the MC simulation.
This thesis has contributed to the achievement of PET/CT imaging as a promising clin-
ical monitoring technique. Data of a well-balanced patient population were evaluated to
identify possible technological and methodological improvements in order to allow for a wide
applicability of PET/CT range verification. PET/CT imaging is currently the only feasible
in vivo and noninvasive way to verify the actual delivered range in three dimensions after
proton treatments. Advanced image guided radiation therapy (IGRT) techniques may allow
to recognize possible sources of range uncertainties, but they can not measure their actual
impact. MC simulation can predict dose distribution with very high precision, but they are
limited in regards to the underlying CT information. Post treatment PET imaging is the
only technique that takes into account all possible source of errors and allows treatment
monitoring in a direct way. The work of this thesis will be continued to provide the benefit
of PET treatment verification to as many patients as possible in clinical routine.
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7.1 Investigation of on line PET measurements
In this thesis activity distributions solely from oﬄine PET measurements were studied. The
delay between the end of treatment and the beginning of PET data acquisition was in av-
erage 15 min. This delay and the fact that patients needed to walk to another building
for the PET scan introduces various uncertainties. The repositioning of the patient at the
PET scanner, for example, causes a slightly different geometry between irradiation and PET
imaging. Furthermore, over time, biological washout processes degrade the induced activity
pattern. To minimize the influence of those uncertainty factors on line PET data acquisition
was proposed [Par08].
In collaboration with the radiology department at MGH we currently testing a movable
NeuroPET scanner (PhotoDetection Systems, Inc [PDS08]) for proton treatment verifica-
tion. This scanner is positioned on wheels and can be moved into the treatment room. The
patient can remain on the treatment couch for the PET scan, merely the position of the
couch has to be rotated and/or shifted (see Figure 7.1). By using the NeuroPET scanner,
the time gap between treatment and imaging can be reduced to one minute. The NeuroPET
scanner has a 305 mm aperture, 270 mm transverse FOV diameter and 240 mm axial FOV.
The relatively small opening allows to image the head or extremities with high precision.
The scanner’s intended use is the diagnosis of brain diseases. Brain tumors, strokes, and
neuron-damaging diseases causing dementia (such as Alzheimer’s disease) change the brain
metabolism. These changes can be detected in PET scans. Because the NeuroPET com-
ponents are compact and require no specialized infrastructure, NeuroPET scanners enable
neurological imaging at lower cost than whole body scanners.
Compared to the PET/CT scanner used throughout this thesis, the NeuroPET scanner
is missing the additional option to take a CT scan for image coregistration. However, since
the patient can remain in the same position during treatment and imaging, the geometry
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variations are expected to be smaller than the uncertainties in the fusion of the planning
and the PET CT. The NeuroPET scanner has a sensitivity of 15 kcps/MBq and a spatial
resolution of 4.3 mm, which is both higher than for the conventional PET/CT scanners.
registration. However, since the patient can remain in the same position during treatment
and imaging, the geometry variations are expected to be smaller than the uncertainties in
the fusion of the planning and the PET CT. The NeuroPET scanner has a sensitivity of 15
kcps/MBq and a spatial resolution of 4.3 mm, which is both higher than for the conventional
PET/CT scanners.
Fig. 7.1: Treatment and PET imaging set up for the use of a NeuroPET scanner shown in the
picture on the right.
The applicability of the NeuroPET scanner for proton treatment verification was recently
tested in a rectangular phantom (9 x 9 x 20 cm, PMMA plastic). The phantom was irradiated
with a proton beam of 5 cm diameter, 16 cm water equivalent range and 10 cm modulation.
A total dose of 8 Gy(RBE) was given. Following irradiation, the phantom was scanned for
30 minutes in the NeuroPET scanner starting 9.5 minutes post exposure. This experiment
was repeated under exactly the same conditions using the conventional PET/CT scanner.
Even though a shorter delay between irradiation and imaging would have been possible for
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the NeuroPET scan, it was chosen to follow the same schedule for both data acquisitions in
order to have comparable results. Figure 7.2 shows the phantom setup at the NeuroPET as
well as at the PET/CT scanner. For image coregistration markers that are recognizable in
the CT as well as in the PET, were used. This is illustrated in the lower row of Figure 7.2.
Fig. 7.2: Pictures in the upper row show the phantom setup during the NeuroPET and the PET/CT
scan. In the activity pattern on the left as well as in the CT image on the right in the
lower row one of six markers used for image coregistration can be seen in the red circles.
Figure 7.3 shows a comparison of activity patterns acquired with the NeuroPET (upper
row) and with the conventional PET/CT scanner (lower row). In the graph on the left, one
can see activity depth profiles at position zero for both scanners. The activity ranges agree
within 2.5 mm at the 50% fall off position.
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Fig. 7.3: Comparison of activity patterns acquired with the NeuroPET (upper row) and with the
conventional PET/CT scanner (lower row). The graph on the left shows activity depth
profiles at position zero for both scanners.
In the 2D-color wash images one can recognize that the activity patterns from the con-
ventional PET/CT scanner look more symmetric and homogeneous than the ones from the
NeuroPET scanner. This could be the result of the different attenuation correction ap-
proaches of the two scanners. While the PET/CT scanner provides a CT image directly
prior the PET data acquisition, the NeuroPET scanner relies on an independently acquired
CT image for attenuation correction. In our phantom experiment, the CT from the PET/CT
scanner was used for attenuation correction of activity patterns of both scanners. While the
phantom was positioned on a card frame at the NeuroPET, it was placed on the patient couch
for imaging at the PET/CT scanner, as seen in Figure 7.2. The CT of the PET/CT scanner
therefore contains the couch contours that were not present in the FOV of the NeuroPET
scanner. The attenuation correction based on the CT with the couch contours therefore
introduces unsymmetries and inhomogeneities in the reconstructed NeuroPET images. To
avoid this source of uncertainties in the future, CT images used for attenuation correction
of the NeuroPET images either have to be corrected for structures that are not present in
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the FOV, or exactly the same setup has to be used during CT and NeuroPET imaging.
Figure 7.4 shows an analysis of the count rate of the two scanners over time. In the left
graph count rates at the isocenter in time frames of 1-2 min up to 1-20 min after the begin of
data acquisition can be seen. In the right graph activity depth profiles over the corresponding
time frames can be seen for both scanners. The NeuroPET scanner shows approximately 1.7
times more counts over the scanning period of 30 minutes than the conventional PET/CT
scanner, reflecting its higher sensitivity. The availability of high count rates from several
chemical species, each with a characteristic life time, could enable to separate the contribu-
tions of each isotope in the reconstructed activity. This way PET imaging could be used to
the rank of a multi-parametric imaging tool.
0 5 10 15 20
2000
3000
4000
5000
6000
7000
8000
9000
10000
min after begin of data acquisition [min]
av
. a
ct
iv
ity
 [B
q/m
l]
count rate at the isocenter
/NeuroPET PET/CT
−50 0 50
0
2000
4000
6000
8000
10000
12000
depth [mm]
ac
tiv
ity
 [B
q/m
l]
/
activity depth profiles averaged about the
1−2 min(dark) up to the 1−20 min(light)
of data acquisition
NeuroPET PET/CT
Fig. 7.4: Left: Average count rate at the isocenter for the 1-2 minute of data acquisition up to the
1-20 minute of data acquisition for the NeuroPET (blue) and the PET/CT (red) scanner.
Right: Activity depth profiles for the same time frames (1-2 minutes dark colors up to
1-20 minutes light colors).
The promising results of the phantom study encourage first in room patient PET scans
following proton treatment. The use of the movable NeuroPET scanner promises to enable
high precision PET treatment verification. Head and neck proton patients could be scanned
routinely, without image degradation due to washout effects or geometrical uncertainties due
to repositioning.
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7.2 Improvement of the biological modeling
For treatment validation the measured PET signal is compared to MC simulated predictions
of the activity pattern. To simulate realistic activity pattern biological washout processes
have to be taken into account. Currently this is done by means of space (i.e., tissue) and
time-dependent weighting factors as described in section 3.2.1.
In collaboration with the Department of Radiation Oncology of the Maastricht Univer-
sity we try to improve our biological washout models. The idea is to use perfusion CT
(CTP) images to obtain characteristic perfusion parameters for different tissues. Perfusion
CT techniques typically require a baseline image acquisition without contrast enhancement
followed by a series of images acquired over time after an intravenous bolus of conventional
iodinated contrast material. The resulting temporal changes in contrast enhancement, often
displayed as timeattenuation curves, are subsequently analyzed to quantify a range of pa-
rameters that reflect the functional status of the vascular system. Pixel-by-pixel analysis can
produce quantitative parametric images with high spatial resolution. CT imaging perfusion
parameters can be generated by using a number of approaches, which can be grouped into
two major methods: compartmental analysis and deconvolution-based methods. Detailed
mathematical and physical principles behind these methods of calculation are available for
review in the literature [Mil03, Cre06, Mil03a, Win01, Cen02, Aks00].
7.3 Expansion of the filtering approach
By filtering the dose distribution along the main beam direction, the approach described in
chapter 3.2.2 allows the calculation of three-dimensional PET distributions induced by pro-
ton beam irradiation. The method has been tested to calculate activity distribution result-
ing from carbon isotopes in homogeneous phantoms and in simple inhomogeneous phantoms
[Par06]. Furthermore preliminary activity distributions for two patient cases were calculated,
which were however restricted to the carbon activity channels and no biological washout or
scanner responds effects were taken into account. On the strength of the promising results
obtained, it would be desirable to extend the approach to more complex inhomogeneous
phantoms. The ultimate goal is to calculate realistic activity distribution with the filtering
method for patient cases taking into account all involved processes.
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The possibility to perform activity measurement shortly after the proton treatment by
means of the NeuroPET scanner as described in chapter 7.1 requires to extend the application
of the filtering approach to short-lived isotopes (mainly 15O and 13N). In collaboration with
the Department of Physics, University of Pisa and INFN Sezione di Pisa and the Heidelberg
Ionenstrahl-Therapie (HIT) Center we currently determine filters for short-lived isotopes. It
is planed to validate the activity distributions resulting from different isotopes and calculated
with these new filter functions with MC simulated as well as with measured distributions.
For the comparison with measured data the idea is to obtain activity distributions for dif-
ferent isotopes from NeuroPET measurements. Due to its high sensitivity, the NeuroPET
scanner provides relatively high count rates. From the accumulated measured activity dis-
tribution it might be possible to separate count rates profiles from several chemical species
due to their characteristic life time.
It is planed to establish a similar Matlab routine for the comparison of the measured
activity distributions with filtered distributions, as used at the moment for the comparison
with MC simulated distributions. This routine would be able to read in activity distribu-
tions from different isotopes calculated by the filtering method and weight and sum them
according to the time line of the corresponding measurement. In addition it would take into
account scanner responds effects and biological washout processes as described in chapter
3.2.1. Calculated activity distributions obtained from the filtering method could then be
used as an alternative to the MC simulated activity distribution to validate the measure-
ments.
In collaboration with the Department of Radiation Oncology, University Medical Cen-
ter Mannheim we also work to improve the results from the inverse filtering approach. An
inversion of the filter functions allows direct dose quantification from the measured PET
distributions. However, this approach requires PET data of excellent signal-to-noise ratio.
We work on different deblurring algorithms and regulators to obtain stable dose distributions
from the measured activity distributions.
Since deblurring is noise sensitive it is necessary to consider the underlying noise distri-
bution. PET is a low-photon imaging technique and thus the activity signals suffer from
Poisson noise. A Richardson-Lucy approach [Ric72, Luc74] is perfectly suited for Poisson
noise and is widely used for astronomy and fluorescence microscopy images containing Pois-
son noise. Furthermore, it is required to add a regularization technique to cope with the
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ill-posed nature of the deblurring problem. A popular choice is a total variation regular-
ization (TV) [Neu98] being able to suppress noise amplifications and artifacts while at the
same time preserving edges. A main issue of the analysis of the dose distribution is an
accurate reconstruction of the distal fall-off region being a sharp edge. The edge preserving
TV regularization is therefore well suited. In addition, using an anisotropic extension to the
regularization favoring sharp edges is very promising to further improve the deblurring result.
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A. WORK FLOW
Figure A.1 shows an outline of the PET/CT range verification approach.
Fig. A.1: Outline of the steps involved in the PET/CT range verification approach. Green numbers
denote processes associated with the data acquisition, blue numbers processes associated
with data simulation. Red parameters act as input into the final Matlab analyzing tool.
A. WORK FLOW
The process of PET/CT range verification consists of many intermediate steps and many
of the involved routines have been developed prior to this work. The framework of the
Geant4 MC simulations is described in [Pag03, Pag04, Pag08] and details of the framework
of the FLUKA simulations can be found in [Par07a, Par07b, Par07c]. In the scope of this
thesis mainly the final analysis routine was expanded. The capability to evaluate difference
plots and to perform a gamma analysis was introduced. For the one dimensional analysis
the shift method described in chapter 3.4.2 was implemented. In the following parts marked
by a number in Figure A.1 are described in detail.
1. Measurement
Prior to patient treatment and imaging, one has to make sure that the treatment position
and fixation is feasible for PET/CT scanning. A printout of the dose fraction helps to speed
up the patient positioning at the PET/CT scanner and to find the optimal bed position that
covers the whole area of interest. At the day of data acquisition, the exact time schedule
of the treatment and PET imaging should be noted to allow for a realistic MC simulation
of the process later. Other parameters that should be recorded are the treatment room and
the number of MU given in each field. At the PET scanner the data should be acquired in
list mode for 31 minutes.
2. Reconstruction
After data acquisition, the PET images should be reconstructed with filtered backpro-
jection (FBP) and ordered-subset expectation maximization (OSEM) algorithms. For later
analysis, the images should be stored with and without attenuation correction. To study
changes in activation over time, the data has to be reconstructed dynamically. In this study
20 time frames of 60 seconds and 5 time frames of 120 second were use for the dynamic
reconstruction.
3. Fusion
The fusion matrix of the planning CT and the PET CT gives information about variations
in the setup during treatment and PET imaging. For the fusion, the PET CT has to be
transfered from the radiology to the proton center via the Picture Archive and Communi-
cation System (PACS), and has to be imported in the FOCAL treatment planning software
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(Computerized Medical Systems, Inc., St. Louis, MO) used at our facility. The FOCAL
software provides a package for rigid image fusion that writes out a fusion matrix.
4. Phase space simulation
As input for the dose as well as for the β+ emitter simulations, ten phase spaces of 1.5
million protons should be simulated with Geant4, as illustrated in Figure A.2. The patient
information from the FOCAL treatment planning software can be preprocessed by a routine
called MC setup. Besides a text file that contains all patient specific parameters, an aperture
file, a compensator file, and the CT data in binary format are produced by this routine. All
these files act as input for the MC phase space simulation. The input file for the MC phase
space simulation can be produced by a script called nozzle in that edits the information of
the text file. The MC phase space simulation is executed by a script called MC PSD. The
resulting phase spaces should be summed up to one file of about one million particles, which
can then be used as input for the dose and β+ emitter simulations.
Fig. A.2: Flow diagram of in-/output parameters and scripts that need to be run to obtain a phase
space file for the dose and β+ emitter simulation.
5. Dose and β+ emitter simulation
The dose and the activity distribution are simulated with FLUKA MC code following the
steps illustrated in Figure A.3. Prior to the actual simulation, a script called link run golem
has to be run. This script needs an input file called writegolem that contains the binary CT
cube with a constant slice thickness and further information about the CT, like the number
of voxels, the voxel dimensions, the position of the isocenter etc... One has to pay attention
to correctly convert these parameters from the CT coordinate system to the FLUKA coordi-
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nate system. The link run golem script gives three geometry parameters and a vxl file that
have to be included in a geometry input file for the actual FLUKA dose and activity simu-
lation. Furthermore, it gives an assigma file that needs to be included in a second input file
together with the phase space file and the setup information like the gantry position or the
couch angle. It is advisable to run the FLUKA dose and activity executable FLUKA 2008
ten times in parallel to gain enough statistic and to compensate for eventual failings of some
runs.
Fig. A.3: Flow diagram of in-/output parameters and scripts that need to be run to obtain dose
and β+ emitter distributions.
6. Absolute dose simulation
To scale the simulated dose and activity distribution correctly, one dose simulation of the
phase space file in a water tank should be performed. The ratio between the simulated dose
in water and the planned dose at the isocenter then gives the correct scaling factor.
7. Format conversion
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To convert the simulated dose and activity distributions to the right format for the final
analysis, a Matlab routine called dose flux should be run. This routine also allows to sum
simulated distributions from different runs.
8. Final analysis
The final analysis is performed by a Matlab routine called PET patient StudyMGH, which
reverts to several subroutines. This routine is capable of comparing the measured and simu-
lated activity distributions as well as the planned and simulated dose distributions as illus-
trated in Figure A.4.
Fig. A.4: In- and output of the final Matlab analyzing script. In the brackets the different steps
performed by the script are listed.
At first it reads in all collected Dicom data and interpolates all the data sets for a sec-
tion that can be defined by the user. The routine will save the fused data in files called
CTPETTP int and PetTP int, and will automatically call these saved files in later runs.
This way the time and resource expensive data handling has to be performed only once. In
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the next step, the biological smoothing of the simulated activity distributions according to
the time schedule of the measurement is performed. The smoothed distribution is stored
in a file called PET smooth global for further use. Finally, the simulated activity distribu-
tion undergoes a convolution to account for scanner response effects and is scaled to the
correct absolute values. The user can then choose between different two-dimensional or one-
dimensional analyzing options.
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